AUTHOR INDEX

(P = proceedings)

ABBOT, P. *see* MADEJ, T. H.
ABBOT, P. *see* SIMPSON, K. H.
ABRAHAM, D. *see* O'NIELL, D.
ABRAMS, S. M. L. *see* JACKSON, S. H. D.
ACTON, G. *see* BROOM, C.
ADVENIER, C. *see* DINH XUAN, A. T.
AHERN, M. J. *see* SALLUSTIO, B. C.
AL-BANNA, M. *see* NIVEN, A. A.
ALEXANDRE, L. *see* DANJOU, P.
AL-FURAIH, T., MCELNAY, J. S., NICHOLLS, D. P., SCOTT, M. G. & STANFORD, C. F. Influence of pH on the buccal absorption of captopril, 656P
ALI, N. J. & WARD, M. J. High dose inhaled beclomethasone dipropionate increases bone resorption in normal men, 634P
AL-KAZWINI, S. L. *see* MARSHALL, I.
ALLEN, E., GHOSE, K., HOGAN, J., RICHENS, A. & WILLIAMS, J. Biperiden pharmacokinetics in young healthy volunteers and elderly parkinsonian patients, 664P
ALLEN, E. *see* HOGAN, J. C.
ALLEN, E. A. *see* MERCER, A.
ALLEN, G. D. *see* GILL, T. S.
ALLEN, M. J. *see* WEBB, D. J.
ALLUE, J. R. *see* DUEÑAS-LAITA, A.
ALMOND, N. E. *see* LI KAM WA, T. C.
AL-SEREITI, M. R. & TURNER, P. Effect of captopril on intracular pressure (IOP) in healthy human volunteers, 659P
AL-WAIZ, M., AYESH, R., MITCHELL, S. C., IDLE, J. R. & SMITH, R. L. Trimethylaminuria: the detection of carriers using a trimethylamine load test, 241P
ANGELI, P. *see* MERKEL, C.
ARNOLD, J. M. O. *see* MCCAFFREY, P. M.
ARNOLD, M. H., PRESTON, S. J. & WATSON BUCHANAN, W. Comparison of the natural history of untreated acute gouty arthritis *vs* acute gouty arthritis treated with non-steroidal anti-inflammatory drugs, 488
ARNOLD, M. H. *see* PRESTON, S. J.
ARVELA, P., KIRJARINTA, M., KÄRKI, N. & PELKONEN, O. Polymorphism of debrisoquine hydroxylation among Finns and Lapps, 601
ASGILL, C. C. A method based on h.p.l.c. for the determination of BRL 37344 in plasma and urine, 228P
ATHOUEL, A. *see* LE NORMAND, Y.
ATKINSON, H. C. & BEGG, E. J. The binding of drugs to major human milk whey proteins, 107
AURICH, R. *see* GOULD, C. A. L.
AXELSON, J. E. *see* WRIGHT, M. R.
AYALA, L. E., CHOUDRY, N. B. & FULLER, R. W. LTD_4-induced bronchoconstriction in patients with asthma: lack of a vagal reflex, 110
AYESH, R. *see* AL-WAIZ, M.
AYESH, R. *see* CHOLERTON, S.
BABER, S. *see* SCIBERRAS, D. G.
BACHMANN, K. A., SCHWARTZ, J. I. & JAUREGUI, L. Predicting the ciprofloxacin-theophylline interaction from single plasma theophylline measurements, 191
BACK, D. J., TIJA, J. F., KARBWANG, J. & COLBERT, J. *In vitro* inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines, 23
BACK, D. J. *see* JENSEN, J. C.
BACK, D. J. *see* PURBA, H. S.
BAILEY, D. G. *see* HARDY, B. G.
BAKSI, A. *see* CROME, P.
BAMBER, P. A. *see* ROWBOTHAM, D. J.
BARNES, N. C. *see* EVANS, J. M.
BARNES, P. J. *see* ROBERTS, N. M.
BARNETT, D. *see* WALLEY, T.
BARNETT, D. B. *see* WALLEY, T. J.
BARRY, M. & FEELY, J. Inhibition of drug metabolism by allopurinol, 649P
BARRY, M. *see* O'REILLY, T.
BARTLE, W. R. *see* HARDY, B. G.
BATEMAN, D. N., RAWLINS, M. D., DARLING, W. M. & BOYS, R. J. Extrapyramidal reactions to metoclopramide and prochlorperazine in general practice, 201P
BATEMAN, D. N. *see* FERNER, R. E.
BATEMAN, D. N. *see* ISAH, A. G.
BATEMAN, D. N. *see* RODGERS, A.
BAX, N. D. S. *see* BURNS, E.
BEASLEY, R. *see* MISZKIEL, K. A.
BEGG, E. J. *see* ATKINSON, H. C.
BELL, G. D., MORDEN, A., COADY, T., LEE, J. & LOGAN, R. F. A comparison of diazepam and midazolam as endoscopy premedication assessing changes in ventilation and oxygen saturation, 595
BELLER, E. M. *see* PRESTON, S. J.
BELZ, G. G., ESSIG, J., KLEINBLOESEM, C. H., HOOGKAMER, J. F. W., WIEGAND, U. W. & WELLSTEIN, A. Interactions between cilazapril and propranolol in man; plasma drug concentrations, hormone and enzyme responses, haemodynamics, agonist dose effect curves and baroreceptor reflex, 547
BEM, J. L., BRECKENRIDGE, A. M., MANN, R. D. & RAWLINS, M. D. Review of yellow cards (1986): report to the Committee on the Safety of Medicines, 679
BENEROSO, N. *see* LE NORMAND, Y.
BENJAMIN, N., CLARKE, J., LARKIN, S., HACKETT, D., WEBB, D. & DAVIES, G. The interaction between neuropeptide Y and noradrenaline in reduction of forearm blood flow, 633P
BENJAMIN, N. *see* SEIDELIN, P. H.
BENJAMIN, N. *see* WEBB, D. J.
BENNETT, A. *see* RILEY, S. A.

BERGSTROM, R. F. *see* FEHER, M. D.
BERNARD, J. M. *see* LE NORMAND, Y.
BERTINO, J. S. JR *see* CERASA, L. A.
BHAMRA, R. K. *see* JOHNSTON, A.
BILL, K. M. & DUNDEE, J. W. Acupressure for post-operative nausea and vomiting, 225P
BIRKETT, D. J. *see* DAY, R. O.
BLACK, G. W. *see* LYNAS, A. G. A.
BLACKBURN, N. A. *see* RODGERS, A.
BLASCHKE, T. F. *see* FORD, G. A.
BOCHNER, F. *see* CHEN, Z. R.
BOCHNER, R. *see* EVANS, A. M.
BOLOGNESE, J. A. *see* SCIBERRAS, D. G.
BOLOGNESI, M. *see* MERKEL, C.
BOOBIS, A. R. *see* SESARDIC, D.
BOON, R. *see* DAVIES, B. E.
BORGSTRÖM, L. *see* JONKMAN, J. H. G.
BOTTORFF, M. B. *see* LALONDE, R. L.
BOYS, R. J. *see* BATEMAN, D. N.
BRADSHAW, C. M. *see* THEOFILOPOULOS, N.
BRECKENRIDGE, A. *see* WALLEY, T.
BRECKENRIDGE, A. M. *see* BEM, J. L.
BRECKENRIDGE, A. M. *see* EDWARDS, G.
BREIMER, D. D. *see* SCHELLENS, J. H. M.
BRIGGS, J. D. *see* NIVEN, A. A.
BROOKS, P. M. *see* PRESTON, S. J.
BROOM, C., ACTON, G., GILL, C. & SPARROW, P. Effects of SK&F 101468, a novel dopamine D_2-receptor agonist, on supine plasma prolactin and haemodynamics in normal man, 654P
BROOM, C., GLENNY, H., PREADY, N., LITKA, P. & WASERMAN, M. First administration of an inhaled leukotriene (LT) antagonist (SK&F 104353-Z2) to normal man, 235P
BROWN, J. *see* WEBB, D. J.
BROWN, K. F. *see* TETT, S. E.
BROWN, M. *see* DAY, R. O.
BROWN, R. A. *see* LIPWORTH, B. J.
BROWN, R. A. *see* SEIDELIN, P. H.
BROWNSILL, R. *see* EDEKI, T. I.
BRUGUEROLLE, B. *see* GIAUFRE, E.
BRUNO, R., ILIADIS, A., JULLIEN, I., GUEGO, M., PINHAS, H., CUNCI, S. & CANO, J. P. Naproxen kinetics in synovial fluid of patients with osteo-arthritis, 41
BRUNOZZI, L. T., MENICONI, L., CHIOCCHI, P., LIBERATI, P., ZUANETTI, G. & LATINI, R. Propafenone in the treatment of chronic ventricular arrhythmias in a pregnant patient, 489
BURGESS, C. D. *see* WARRINGTON, S. J.
BURKE, T. A. & SANGER, G. J. Regionally selective cholinergic stimulation by BRL 24924 in the human isolated gut, 261
BURNS, E., WYLD, P. J. & BAX, N. D. S. Patients' knowledge of their drug therapy and its possible risks, 622P

CAMERON, G. A. *see* SCOTT, A. K.
CAMERON, H. A., WALLER, P. C. & RAMSAY, L. E. Drug treatment of intermittent claudication: A critical analysis of the methods and findings of published clinical trials, 1965–1985, 569
CAMPBELL, D. B. *see* EDEKI, T. I.
CAMPBELL, G. A., MORGAN, D. J., KUMAR, K. & CRANKSHAW, D. P. Extended blood collection period required to define distribution and elimination kinetics of propofol, 187
CANO, J. P. *see* BRUNO, R.
CARMODY, M. *see* KELLY, J. G.
CARR, C. M. E. *see* MADEJ, T. H.
CARR, C. M. E. *see* SIMPSON, K. H.
CARRUTHERS, S. G. *see* POLLAK, P. T.
CASTLEDEN, C. M. & PICKLES, H. Suspected adverse drug reactions in elderly patients reported to the Committee on Safety of Medicines, 347
CEDAR, E. *see* COURTNEY, T. P.
CERASA, L. A., BERTINO, J. S. JR, LUDWIG, E. A., SAVLIWALA, M., MIDDLETON, E. JR & SLAUGHTER, R. L. Lack of effect of atenolol on the pharmacokinetics of theophylline, 800
CHALLENOR, V. F., WALLER, D. G., HAYWARD, R. A., GRIFFIN, M. J. & ROATH, O. S. Nifedipine dose titration in primary Raynaud's phenomenon, 633P
CHAMPION, G. D. *see* DAY, R. O.
CHAN, K., CHIU, H., LEE, S., CHEN, N. & CRAMMER, J. Estimating plasma concentrations of desipramine in Chinese depressed patients using the repeated one-point method, 638P
CHAN, R. *see* FEELY, J.
CHAPUT DE SAINTONGE, D. M., KIRWAN, J. R., EVANS, S. J. W. & CRANE, G. J. How can we design trials to detect clinically important changes in disease severity?, 355
CHEN, C. N. *see* CHAN, K.
CHEN, Z. R., BOCHNER, F. & SOMOGYI, A. Pharmacokinetics of pholocodine in healthy volunteers: single and chronic dosing studies, 445
CHEUNG, R., NICHOLSON, P. W., DICKINS, J., DESHMUKH, A. A., O'NEILL, C. J. A., DOBBS, R. J. & DOBBS, S. M. Value of a pill box with a concealed monitoring device in a clinical trial and in routine practice, 661P
CHEUNG, R., SULLENS, C. M., SEAL, D., DICKINS, J., NICHOLSON, P. W., DESHMUKH, A. A., DENHAM, M. J. & DOBBS, S. M. The paradox of using a 7 day antibacterial course to treat urinary tract infections in the community, 391
CHIOCCHI, P. *see* BRUNOZZI, L. T.
CHIU, H. *see* CHAN, K.
CHOLERTON, S., AYESH, R., IDLE, J. R. & SMITH, R. L. The pre-eminence of nicotine N-oxidation and its diminution after carbimazole administration, 652P
CHOONARA, I. A. The value of serum anticonvulsant levels in paediatric outpatients, 233P
CHOUDRY, N. B. *see* AYALA, L. E.
CHRISTIE, G. & PARK, B. K. The detection of anti-amodiaquine antibodies by ELISA, 624P
CHRISTIE, P. R. *see* GREEN, S. T.
CHUNG, K. F. *see* ROBERTS, N. M.
CLARK, R. A. *see* LIPWORTH, B. J.
CLARKE, J. *see* BENJAMIN, N.
CLARKE, R. S. J. *see* LYNAS, A. G. A.
CLERICI, C. *see* MACQUIN-MAVIER, I.
COADY, T. *see* BELL, G. D.
COAKLEY, D. *see* O'NIELL, D.

COATES, P., MCKELLAR, J. & MILLER, A. J. Once nightly sustained release theophylline in elderly subjects, 613
COBB, S. M. *see* HOGG, K. J.
COCKCROFT, J. R. *see* WEBB, D. J.
COLBERT, J. *see* BACK, D. J.
COLBERT, J. *see* KITTERINGHAM, N. R.
COLEMAN, J. W. *see* PARK, B. K.
COLEMAN, J. W. *see* WINSTANLEY, P. A.
COLLIER, J., FAULKNER, J. K., RANCE, D. J. & MESURE, R. Single dose tolerance and pharmacokinetics of oral UK-61.260, a novel inotrope/vasodilator, 669P
CONNOLLY, M. *see* FERNER, R. E.
COOK, P. J. *see* EVANS, C. D.
COOKE, E. D. *see* LI KAM WA, T. C.
COOPER, W. D. *see* GLOVER, D. R.
COOPER, W. D. *see* KELLY, J. G.
COPELAND, S., RIDDELL, J. G. & SHANKS, R. G. The effect of fenoterol and its enantiomers on cyclic AMP production by human lymphocytes, 676P
COSTELLO, J. G. *see* EVANS, J. M.
COTTON, M. *see* MACDONALD, T. M.
COULTHARD, K. *see* MILNE, R. W.
COURTNEY, T. P., SHAW, R. W., CEDAR, E., MANN, S. G. & KELLY, J. G. Excretion of famotidine in breast milk, 639P
COUTIE, W. *see* LIPWORTH, B. J.
CRAIG, R. K. *see* MARSHALL, I.
CRAMMER, J. *see* CHAN, K.
CRANE, G. J. *see* CHAPUT DE SAINTONGE, D. M.
CRANKSHAW, D. P. *see* CAMPBELL, G. A.
CREAN, P. A. *see* GRAY, R. P.
CREWE, H. K., OTTON, S. V., LENNARD, M. S., TUCKER, G. T. & WOODS, H. F. The kinetics of oxidation of metoprolol enantiomers by human liver microsomes, 655P
CRITCHLEY, J. A. J. H. *see* SPEIRS, G. C.
CROME, P., BAKSI, A., MACMAHON, D., PANDITA-GUNAWARDENA, N. D., EDWARDS, J. & MARLEY, J. Plasma nitrendipine concentrations in elderly hypertensive patients after single and multiple dosing, 323
CROME, P. & WHITE, A. S. T. The pharmacokinetics and tolerance of single doses of UK-61, 260 in healthy elderly subjects, 670P
CROME, P. *see* FLANAGAN, R. J.
CROSSMAN, D. C. & FULLER, R. W. Bradykinin induced wheal and flare is not mediated by histamine release or cyclooxygenase products, 113
CRUICKSHANK, J. M. *see* TOMLINSON, B.
CUNCI, S. *see* BRUNO, R.
CURRIE, D., LEWIS, R. V., MCDEVITT, D. G., NICHOLSON, A. N. & WRIGHT, N. A. Central effects of β-adrenoceptor antagonists I-Performance and subjective assessments of mood, 121
CURRIE, D. *see* NICHOLSON, A. N.
CUTLER, D. J. *see* TETT, S. E.

DANHOF, M. *see* SCHELLENS, J. H. M.
DANIOTTI, S. *see* IMBIMBO, B. P.
DANJOU, P., ALEXANDRE, L., WAROT, D., LACOMBLEZ, L. & PEUCH, A. J. Assessment of erectogenic properties of apomorphine and yohimbine in man, 733
D'ARCY, P. F. *see* PASSMORE, C. M.
DARLEY, C. R. *see* GREEN, K. L.
DARLING, W. M. *see* BATEMAN, D. N.
DAVIES, B. E., BOON, R., HORTON, R., REUBI, F. C. & DESCOEUDRES, C. E. Pharmacokinetics of amoxycillin and clavulanic acid in haemodialysis patients following intravenous administration of Augmentin, 385
DAVIES, B. E. *see* GILL, T. S.
DAVIES, D. L. *see* MURDOCH, D. L.
DAVIES, D. S., MILLS, F. J. & WELBURN, P. J. Cisapride has no effect on antipyrine clearance, 808
DAVIES, D. S. *see* SESARDIC, D.
DAVIES, G. *see* BENJAMIN, N.
DAVIES, J. A. *see* KUMAR, S.
DAVIES, M. G., MCCOLLUM, P. T., KENT, P., FEELY, M., O'DRISCOLL, K., MOORE, D. J. & SHANIK, G. D. Intravenous pentoxifylline increases tissue oxygenation in the treatment of established ischaemic rest pain, 650P
DAVIES, M. G., ROWAN, M. J., MATHUNA, P. M., KEELING, P. W. N., WEIR, D. G. & FEELY, J. Use of the P300 event related potential in the assessment of early hepatic encephalopathy, 647P
DAVIES, R. J. *see* GOULD, C. A. L.
DAVIS, S. S., WASHINGTON, N., PARR, G. D., SHORT, A. H., JOHN, V. A., LLOYD, P. & WALKER, S. M. Relationship between the rate of appearance of oxprenolol in the systemic circulation and the location of an oxprenolol Oros 16/260 drug delivery system within the gastrointestinal tract as determined by scintigraphy, 435
DAY, R. O., HARRIS, G., BROWN, M., GRAHAM, G. G. & CHAMPION, G. D. Interaction of salicylate and corticosteroids in man, 334
DAY, R. O., MINERS, J. O., BIRKETT, D. J., WHITEHEAD, A., NAIDOO, D., HAYES, J. & SAVDIE, E. Allopurinol dosage selection: relationships between dose and plasma oxipurinol and urate concentrations and urinary rate excretion, 423
DAY, R. O., MINERS, J., BIRKETT, D. J., GRAHAM, G. G. & WHITEHEAD, T. Relationship between plasma oxipurinol concentrations and xanthine oxidase activity in volunteers dosed with allopurinol, 429
DAY, R. O., PAULL, P. D., LAM, S., SWANSON, B. R., WILLIAMS, K. M. & WADE, D. N. The effect of concurrent aspirin upon plasma concentrations of tenoxicam, 455
DAY, R. O. *see* TETT, S. E.
DEANEY, N. B. *see* KELLY, J. G.
DE MEY, C. & ENTERLING, D. Limitations in the non-invasive assessment of the cardiovascular responses to i.v. infusion of phenylephrine in normal man, 232P
DENHAM, M. J. *see* CHEUNG, R.
DE NOORD, O. E. *see* JONKMAN, J. H. G.
DESAI, N. K. *see* NAYAK, V. K.
DESCOEUDRES, C. E. *see* DAVIES, B. E.
DESHMUKH, A. A. *see* CHEUNG, R.
DEVANEY, N. *see* KING, D. J.
DE VILLEPOIX, C. *see* LE NORMAND, Y.
DHILLON, D. P. *see* LIPWORTH, B. J.
DICKINS, J. *see* CHEUNG, R.

DINGSDALE, A. *see* EDWARDS, G.
DINH XUAN, A. T., MATRAN, R., REGNARD, J., VITOU, P., ADVENIER, C. & LOCKHART, A. Comparative effects of rilmenidine and clonidine on bronchial responses to histamine in asthmatic subjects, 703
DIXON, M. S., THOMAS, P., WINTERTON, S. J. & SHERIDAN, D. J. Acute haemodynamic effects of cromakalim, a novel vasodilator, in patients with ischaemic heart disease, 640P
DOBBS, R. J. *see* CHEUNG, R.
DOBBS, S. M. *see* CHEUNG, R.
DOLLERY, C. T. *see* WARREN, J. B.
DONNELLY, R., ELLIOTT, H. L., MEREDITH, P. A., HUGHES, D. M. A. & REID, J. L. Ketanserin concentration-effect relationships in individual hypertensive patients, 61
DOYLE, G. D. *see* KELLY, J. G.
DUEÑAS-LAITA, A., POZUELO, A., ESCUDERO, J. C. M. & ALLUE, J. R. Side effects of long-term amiodarone therapy at low maintenance doses, 671P
DUGGAN, J., KILFEATHER, S., LIGHTMAN, S. & O'MALLEY, K. The effect of age on platelet angiotensin II and ANP receptor density, 629P
DUGGAN, J., KILFEATHER, S. & O'MALLEY, K. The effect of age on platelet intracellular free calcium concentration, 653P
DULY, E. *see* DWYER, R.
DUNCAN, J. S. *see* PATSALOS, P. N.
DUNDEE, J. W. *see* BILL, K. M.
DUNDEE, J. W. *see* DWYER, R.
DURNIN, C. J. *see* EDWARDS, A. A.
DURNIN, C. J. *see* QURESHI, M. Z.
DWYER, R. FLYNN, R. J., DULY, E., MOORE, J. & DUNDEE, J. W. The effect of labour and epidural analgesia on plasma concentrations of drug binding proteins, 635P

EDEKI, T. I., JOHNSTON, A., CAMPBELL, D. B., INGS, R. M. J., BROWNSILL, R., GENISSEL, P. & TURNER, P. An examination of the possible pharmacokinetic interaction of trimetazidine with theophylline, digoxin and antipyrine, 657P
EDEKI, T. *see* LI KAM WA, T. C.
EDEKI, T. I. *see* SALEH, S.
EDELMAN, J. *see* REEVES, P. T.
EDGAR, B. *see* HARDY, B. G.
EDWARDS, A. A., MORELAND, T. A., DURNIN, C. J. & MCEWEN, J. Mechanism of action of glipizide: evidence for glucose-modulated insulin release in healthy subjects, 240P
EDWARDS, G., DINGSDALE, A., ORME, M. L'E. & BRECKENRIDGE, A. M. Relative bioavailability of ivermectin administration as capsule, tablet and oral solution, 225P
EDWARDS, J. *see* CROME, P.
EDWARDS, J. G. *see* UPWARD, J. W.
EDWARDS, R. J. *see* SESARDIC, D.
EFTHYMIOPOULOS, C. *see* KIRCH, W.
EICHLER, H-G. *see* FORD, G. A.
EISALO, A. *see* KOSKINEN, P.
ELBORN, J. S. *see* TULLY, M. P.
ELLIOTT, H. L. *see* DONNELLY, R.
ELLIOTT, H. L. *see* HOGG, K. J.
ELLIOTT, H. L. *see* SUMNER, D. J.
ELLIS, F. R. *see* MADEJ, T. H.
ELLIS, F. R. *see* SIMPSON, K. H.
ENTERLING, D. *see* DE MEY, C.
ESCUDERO, J. C. M. *see* DUEÑAS-LAITA, A.
ESSIEN, E. S. *see* ETTE, E. I.
ESSIG, J. *see* BELZ, G. G.
ETTE, E. I., OGONOR, J. I. & ESSIEN, E. S. Passage of chloroquine into semen, 179
EVANS, A. M., NATION, R. L., SANSOM, L. N., BOCHNER, F. & SOMOGYI, A. A. Stereoselective drug disposition: potential for misinterpretation of drug disposition data, 771
EVANS, C. D., FACCHINI, V., PAGE, K. M., COOK, P. J. & JAMES, I. M. A comparison of plasma concentrations observed following repeat oral administration of zopiclone or flurazepam in the elderly, 673P.
EVANS, J. M., BARNES, N. C., ZAKRZEWSKI, J. T., GLENNY, H. P., PIPER, P. J. & COSTELLO, J. F. Effects of an inhaled leukotriene (LT) antagonist, SK&F 104353–Z2 on LTD_4 and histamine induced bronchoconstriction in normal man, 677P
EVANS, S. J. W. *see* CHAPUT DE SAINTONGE, D. M.

FACCHINI, V. *see* EVANS, C. D.
FARID, N. A. *see* FEHER, M. D.
FAULKNER, J. K. *see* COLLIER, J.
FEELEY, M. *see* PENN, N. D.
FEELY, J., CHAN, R., O'CONNOR, P. & MULPETER, K. Diminishing compliance with a hospital formulary in the absence of continuous feedback of information to prescribers, 616P
FEELY, J. *see* BARRY, M.
FEELY, J. *see* DAVIES, M. G.
FEELY, J. *see* MCGRATH, A.
FEELY, J. *see* O'BYRNE, S.
FEELY, J. *see* O'CONNOR, P.
FEELY, J. *see* O'NIELL, D.
FEELY, J. *see* O'REILLY, T.
FEELY, M., KUMAR, S., TINDALL, H. & PULLAR, T. Assessing compliance: is return tablet count worthwhile?, 641P
FEELY, M. *see* DAVIES, M. G.
FEELY, M. *see* KUMAR, S.
FEHER, M. D., LUCAS, R. A., FARID, N. A., IDLE, J. R., BERGSTROM, R. F., LEMBERGER, L. & SEVER, P. S. Single dose pharmacokinetics of tomoxetine in poor and extensive metabolisers of debrisoquine, 231P
FERNER, R. E., WARD, C., KELLY, C., CONNOLLY, M., BATEMAN, D. N. & RAWLINS, M. D. Reversal of histamine-induced bronchoconstriction by the H_1-receptor antagonist levocabastine: A potential model for efficacy in anaphylaxis, 509
FINUCCI, G. F. *see* MERKEL, C.
FITZPATRICK, K. T. J. *see* LYNAS, A. G. A.
FLANAGAN, R. J., JOHNSTON, A., WHITE, A. S. T. & CROME, P. Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene after coproxamol dosage in young and elderly volunteers, 660P
FLYNN, R. J. *see* DWYER, R.
FOLEY, J. B. *see* GRAY, R. P.

FORD, G. A., EICHLER, H-G., HOFFMAN, B. B. & BLASCHKE, T. F. Venous responsiveness to atrial natriuretic factor in man, 797
FOX, J. *see* GILL, T. S.
FRABOUL, J. P. *see* LE NORMAND, Y.
FREESTONE, S. *see* MCAUSLANE, J. A. N.
FRIEDRICH, G. *see* HARTMAN, D.
FULLER, R. W. *see* AYALIA, L. E.
FULLER, R. W. *see* CROSSMAN, D. C.
FULLER, R. W. *see* WARREN, J. B.

GALLOWAY, D. B. *see* MCVEIGH, G. E.
GATTA, A. *see* MERKEL, C.
GENISSEL, P. *see* EDEKI, T. I.
GENTRY, R. B. *see* GLOVER, D. R.
GEORGE, A. J., RAVINDRAN, A. V. & PHILPOTT, R. M. Plasma growth hormone concentration and urinary MHPG excretion in dementia and depression, 202P
GEORGE, C. *see* MACQUIN-MAVIER, I.
GEORGE, C. F. *see* ROBERTSON, D. R. C.
GERTZ, B. J. *see* WARREN, J. B.
GHOSE, K. *see* ALLEN, E.
GIAUFRE, E., BRUGUEROLLE, B., MORRISON-LACOMBE, G. & ROUSSET-ROUVIERE, B. The influence of diazepam on the plasma concentrations of bupivacaine and lignocaine after caudal injection of a mixture of the local anaesthetics in children, 116
GILL, C. *see* BROWN, C.
GILL, T. S., ALLEN, G. D. & DAVIES, B. E. A stereospecific GC-MS assay for cromakalim enantiomers in plasma and urine, 227P
GILL, T. S., DAVIES, B. E., TASKER, T. C. G., WHITEHEAD, E. M., FOX, J. & SHANKS, R. G. Stereospecific pharmacokinetics of cromakalim enantiomers at various oral dose levels, in healthy male subjects, 658P
GILLAN, G. J. *see* MURDOCH, D. L.
GLADZIWA, U., KLOTZ, U., KRISHNA, D. R., SCHMITT, H., GLÖCKNER, W. M. & MANN, H. Pharmacokinetics and dynamics of famotidine in patients with renal failure, 315
GLENNY, H. *see* BROOM, C.
GLENNY, H. P. *see* EVANS, J. M.
GLÖCKNER, W. M. *see* GLADZIWA, U.
GLOVER, D. R., GENTRY, R. B., SMART, W. & COOPER, W. D. What is the best treatment strategy for patients whose hypertension is not controlled by enalapril 20 mg once daily?, 632P
GLOVER, D. R. *see* KELLY, J. G.
GOLDBERG, D. J. *see* GREEN, S. T.
GOLDIE, A. *see* UPWARD, J. W.
GOULD, C. A. L., OLLIER, S., AURICH, R. & DAVIES, R. J. A study of the clinical efficacy of azelastine in patients with extrinsic asthma, and its effect on airway responsiveness, 515
GRAHAM, B. R. *see* RENONDIN, J. C.
GRAHAM, B. R. *see* TOMLINSON, B.
GRAHAM, G. G. *see* DAY, R. O.
GRAHAM, P. *see* GREEN, K. L.
GRAY, R. P., FOLEY, J. B., MOORE, D. P., CREAN, D. A. & WALSH, M. J. Haemodynamic and dose related efficacy and tolerance of an orally administered MCI-154 in patients with chronic heart failure, 669P
GREEN, K. L., SAPRA, M., GRAHAM, P., HARRIS, J. M. & DARLEY, C. R. Topical salbutamol in atopic eczema, 646P
GREEN, S. T., GOLDBERG, D. J., LEACH, J., CHRISTIE, P. R. & KENNEDY, D. H. AIDS-related *Pneumocystis carinii* pneumonia successfully treated with dapsone-trimethoprim, 487
GREVEL, J. *see* NIVEN, A. A.
GRIFFIN, M. J. *see* CHALLENOR, V. F.
GRIFFITHS, A. P. *see* PENN, N. D.
GROB, P. R. *see* SALEK, M. S.
GUEGO, M. *see* BRUNO, R.

HACKETT, D. *see* BENJAMIN, N.
HAGUE, D. & SMITH, R. L. Enigmatic properties of (±)-thalidomide an example of a stable racemic compound, 623P
HAIGH, J. R. M. *see* KUMAR, S.
HALLAM, A., MANSEL, R. E., MILLER, W. R., NICHOLLS, P. J. & SMITH, H. J. Preliminary investigations of the effect of 4-pyridylglutethimide on aromatase in breast carcinomas, 663P
HANRAHAN, P. *see* REEVES, P. T.
HARDY, B. G., BARTLE, W. R., MYERS, M., BAILEY, D. G. & EDGAR, B. Effect of indomethacin on the pharmacokinetics and pharmacodynamics of felodipine, 557
HARF, A. *see* MACQUIN-MAVIER, I.
HARRIS, G. *see* DAY, R. O.
HARRIS, J. M. *see* GREEN, K. L.
HARRY, J. D. *see* MILLSON, D. S.
HARTMAN, D., LUNELL, N.-O., FRIEDRICH, G. & RANE, A. Excretion of tiapamil in breast milk, 183
HAWKEY, C. J. *see* PRICHARD, P. J.
HAWKSWORTH, G. M. *see* SCOTT, A. K.
HAWORTH, S. J. *see* MILLSON, D. S.
HAYES, J. *see* DAY, R. O.
HAYES, Y. *see* TOMLINSON, B.
HAYWARD, R. A. *see* CHALLENOR, V. F.
HENDRIKS, R. *see* VERONESE, M. E.
HERMAN, R. J. *see* LOEWEN, G. R.
HERXHEIMER, A. Misuse of the standard error of the mean, 197
HICKEY, A. *see* MCGEE, H.
HIGGS, G. A. Topical indomethacin and psoriasis, 119
HIMBERG, J-J. *see* TOKOLA, O.
HOARE, R. C. *see* HOLLAND, I. S.
HOFFMAN, B. B. *see* FORD, G. A.
HOGAN, J. *see* ALLEN, E.
HOGAN, J. C., ALLEN, E., YEANG, Y., WALLIS, C. & LEWIS, M. J. A single blind placebo controlled crossover safety study of 42068RP in healthy volunteers, 664P
HOGG, K. J., THOMSON, A., ELLIOTT, H. L., COBB, S. M. & REID, J. L. The pharmacokinetics and pharmacodynamics of a new class III antiarrhythmic UK66,914—results of a phase I study, 672P
HOLGATE, S. T. *see* MISZKIEL, K. A.
HOLLAND, I. S., SEYMOUR, R. A., WARD-BOOTH, R. P., ORD, R. A., LIM, K. L. M. & HOARE, R. C. An evaluation of different doses of soluble aspirin and aspirin tablets in postoperative dental pain, 463

HOLMAN, J. J. *see* MARSHALL, I.
HOLT, D. W. *see* JOHNSTON, A.
HOOGKAMER, J. F. W. *see* BELZ, G. G.
HORAI, Y., ISHIZAKI, T. & ISHIKAWA, K. Metoprolol oxidation in a Japanese population: evidence for only one poor metaboliser among 262 subjects, 807
HORTON, R. *see* DAVIES, B. E.
HOSIE, G. A. C. *see* HOSIE, J.
HOSIE, J. & HOSIE, G. A. C. Differences in the pharmacokinetics of ketoprofen between elderly women and elderly men, 210P
HOUTMAN, P. N. & RYLANCE, G. W. Pharmacokinetics of ranitidine syrup in children, 637P
HOWARD, M. *see* KUMAR, S.
HOWDEN, C. W. *see* TSAI, H. H.
HOWIE, C. A. *see* SUMNER, D. J.
HUGHES, D. M. A. *see* DONNELLY, R.
HUNG, S. O. *see* TIONG, T. H.
HUTCHINGS, A. *see* LITTLEY, M. D.
HUUPONEN, R. *see* KALLIO, J.

IDLE, J. R. *see* AL-WAIZ, M.
IDLE, J. R. *see* CHOLERTON, S.
IDLE, J. R. *see* FEHER, M. D.
IISALO, E. *see* KALLIO, J.
ILETT, K. F. *see* REEVES, P. T.
ILIADIS, A. *see* BRUNO, R.
IMBIMBO, B. P., URSO, R., THIEME, G., STURN, B., UECKERT, B., VIDI, A., LADINSKY, H. & DANIOTTI, S. Pharmacokinetics of mifentidine after single and multiple oral administration to healthy volunteers, 407
INGS, R. M. J. *see* EDEKI, T. I.
IOANNIDES, C. *see* LEWIS, R.
ISAH, A. G., BATEMAN, D. N. & RAWLINS, M. D. The effect of coproxamol on metoclopramide induced restlessness and prolactin response, 220P
ISHIKAWA, K. *see* HORAI, Y.
ISHIZAKI, T. *see* HORAI, Y.
IYUN, A. O. *see* LENNARD, M. S.

JACKSON, N. C. *see* ZEZULKA, A. V.
JACKSON, P. R., LENNARD, M. S., TUCKER, G. T. & WOODS, H. F. Testing for bimodality in frequency distributions of data suggesting polymorphisms of drug metabolism-probit plots, 233P
JACKSON, P. R., LENNARD, M. S., TUCKER, G. T. & WOODS, H. F. Testing for bimodality in distributions of data suggesting polymorphisms of drug metabolism-hypothesis testing, 234P
JACKSON, P. R., TUCKER, G. T. & WOODS, H. F. Backtracking booze with Bayes, 676P
JACKSON, P. R. *see* LEWIS, R. V.
JACKSON, S. H. D., JOHNSTON, A., WOOLLARD, R., ABRAMS, S. M. L. & TURNER, P. Circadian variation in theophylline absorption during chronic dosing with a slow release theophylline preparation and the effect of clock time of dosing, 73
JAMES, I. *see* SCIBERRAS, D. G.
JAMES, I. M. *see* EVANS, C. D.
JANTUNEN, M. E. *see* PIHLAJAMÄKI, K. K.
JAUREGUI, L. *see* BACHMANN, K. A.
JENSEN, J. C. & BACK, D. J. Interaction of terbinafine with cytochrome P-450 *in vitro* and *in vivo* in man, 236P
JOFFE, H. S. *see* JOHNSTON, A.
JOHN, V. A. *see* DAVIS, S. S.
JOHNSTON, A., BHAMRA, R. K., TILL, J. A., WARD, D. E., SHINEBOURNE, E. A., JOFFE, H. S. & HOLT, D. W. Pharmacokinetics of flecainide in children, 216P
JOHNSTON, A., BHAMRA, R. K., ROBINSON, K., MCKENNA, W. J., KRIKLER, D. M. & HOLT, D. W. Propafenone therapy: relationship between plasma concentrations and clinical effect, 629P
JOHNSTON, A. *see* EDEKI, T. I.
JOHNSTON, A. *see* FLANAGAN, R. J.
JOHNSTON, A. *see* JACKSON, S. H. D.
JOHNSTON, A. *see* LEWIS, R.
JOHNSTON, A. *see* SALEH, S.
JOHNSTON, G. D. *see* MCVEIGH, G. E.
JOHNSTON, G. D. *see* WHITEHEAD, E. M.
JONES, P. W. *see* SWINBURN, C. R.
JONKMAN, J. H. G., BORGSTRÖM, L., VAN DER BOON, M. J. V. & DE NOORD, O. E. Theophylline-terbutaline, a steady state study on possible pharmacokinetic interactions with special reference to chronopharmacokinetic aspects, 285
JOYCE, C. R. B. *see* MCGEE, H.
JULLIEN, I. *see* BRUNO, R.
JUNG, L. *see* KIRCH, W.

KALLIO, J., LINDBERG, R., HUUPPONEN, R. & IISALO, E. Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio, 791
KARBWANG, J., *see* BACK, D. J.
KÄRKI, M. *see* ARVELA, P.
KASER-LIARD, B. *see* SUTCLIFFE, F. A.
KEELING, P. W. N. *see* DAVIES, M. G.
KEELING, P. W. N. *see* O'REILLY, T.
KELLAWAY, I. W. *see* TAYLOR, K. M. G.
KELLMAN, A. W. *see* NIVEN, A. A.
KELLY, C. *see* FERNER, R. E.
KELLY, J. G., DOYLE, G. D., CARMODY, M., GLOVER, D. R. & COOPER, W. D. Pharmacokinetics of lisinopril, enalapril and enalaprilat in renal failure, 781
KELLY, J. G., DEANEY, N. B., LAVAN, J. & NOEL, J. Chronic dose urinary and serum pharmacokinetics of norfloxacin in the elderly, 787
KELLY, J. G. *see* COURTNEY, T. P.
KENNEDY, D. H. *see* GREEN, S. T.
KENSINGTON, J. *see* MACHONOCHIE, J.
KENT, P. *see* DAVIES, M. G.
KERR, F. A. *see* THEOFILOPOULOS, N.
KHAN, F., STRUTHERS, A. D. & SPENCE, V. A. The effect of prazosin on skin microcirculation as assessed by laser Doppler flowmetry, 267
KHAN, F. *see* STRUTHERS, A. D.
KHIR, A. S. M. *see* SCOTT, A. K.
KILFEATHER, S. *see* DUGGAN, J.
KING, D. J. & DEVANEY, N. Clinical pharmacology of sibutramine hydrochloride (BTS 54524), a new antidepressant, in healthy volunteers, 617

KIRCH, W., LASKOWSKI, M. & OHNHAUS, E. E. The felodipine/digoxin interaction. A placebo-controlled study in patients with heart failure, 644P
KIRCH, W., MILFERSTADT, S., ROCHER, I., EFTHYMIOPOULOS, C. & JUNG, L. Influence of rifampicin and ranitidine on circadian blood pressure and pharmacokinetics of tertatolol in hypertensives, 643P
KIRJARINTA, M. *see* ARVELA, P.
KIRWAN, J. R. *see* CHAPUT DE SAINTONGE, D. M.
KITTERINGHAM, N. R., LAMBERT, C., MAGGS, J. L., COLBERT, J. & PARK, B. K. A comparative study of the formation of chemically reactive drug metabolites by human liver microsomes, 13
KITTERINGHAM, N. R. *see* LAMBERT, C.
KITTERINGHAM, N. R. *see* MAGGS, J. L.
KITTERINGHAM, N. R. *see* RILEY, R. J.
KLEINBLOESEM, C. H. *see* BELZ, G. G.
KLOTZ, U. *see* GLADZIWA, U.
KOSKINEN, P., MANNINEN, V. & EISALO, A. Quinapril and blood lipids, 478
KRIKLER, D. M. *see* JOHNSTON, A.
KRISHNA, D. R. *see* GLADZIWA, U.
KSHIRSAGAR, N. A. *see* NAYAK, V. K.
KUMAR, K. *see* CAMPBELL, G. A.
KUMAR, S., HAIGH, J. R. M., HOWARD, M., PEAKER, S., DAVIES, J. A., ROBERTS, B. E. & FEELY, M. Poor compliance appears to be the major cause of unstable anticoagulation with warfarin, 620P
KUMAR, S. *see* FEELY, M.

LACOMBLEZ, L. *see* DANJOU, P.
LADINSKY, H. *see* IMBIMBO, B. P.
LALONDE, R. L., BOTTORFF, M. B., STRAKA, R. J., TENERO, D. M., PIEPER, J. A. & WAINER, I. W. Nonlinear accumulation of propranolol enantiomers, 100
LAM, S. *see* DAY, R. O.
LAMB, R. *see* WOODS, C. G.
LAMBERT, C., PARK, B. K. & KITTERINGHAM, N. R. Stereoselective metabolism and irreversible binding of mianserin by human liver microsomes, 665P
LAMBERT, C. *see* KITTERINGHAM, N. R.
LAMBERT, C. *see* MAGGS, J. L.
LAMBERT, C. *see* RILEY, R. J.
LANT, A. F. *see* MCNABB, W. R.
LARKIN, S. *see* BENJAMIN, N.
LAROUSSE, C. *see* LE NORMAND, Y.
LASKOWSKI, M. *see* KIRCH, W.
LATINI, R. *see* BRUNOZZI, L. T.
LAVAN, J. *see* KELLY, J. G.
LAVENS, S. E. *see* TINGLE, M. D.
LAZARUS, J. H. *see* LITTLEY, M. D.
LEACH, J. *see* GREEN, S. T.
LECKIE, B. *see* MURDOCH, D. L.
LEE, J. *see* BELL, G. D.
LEE, S. *see* CHAN, K.
LEENEN, F. H. H., SMITH, D. L. & UNGER, W. P. Topical minoxidil: cardiac effects in bald men, 481
LEES, K. R. *see* TSAI, H. H.
LEES, K. R. & REID, J. L. Influence of age on the pharmacokinetics and pharmacodynamics of perindopril, 211P
LEMBERGER, L. *see* FEHER, M. D.
LENNARD, M. S., TUCKER, G. T., WOODS, H. F., SILAS, J. H. & IYUN, A. O. Oxidation phenotype and the stereoselective metabolism of metoprolol in Caucasians and Nigerians, 230P
LENNARD, M. S. *see* CREWE, H. K.
LENNARD, M. S. *see* JACKSON, P. R.
LE NORMAND, Y., DE VILLEPOIX, C., PINAUD, M., BERNARD, J. M., FRABOUL, J. P., ATHOUEL, A., RIBEYROL, M., BENEROSO, N. & LAROUSSE, C. Pharmacokinetics and haemodynamic effects of prolonged methohexitone infusion, 589
LEWIS, M. J. *see* HOGAN, J. C.
LEWIS, M. J. *see* SALEK, M. S.
LEWIS, R., MACLEAN, D., IOANNIDES, C., JOHNSTON, A. & MCDEVITT, D. G. A comparison of bisoprolol and atenolol in the treatment of mild to moderate hypertension, 53
LEWIS, R. V., MCMURRAY, J. & MCDEVITT, D. G. Effects of verapamil, atenolol and xamoterol in digitalised patients with atrial fibrillation, 213P
LEWIS, R. V. & MCDEVITT, D. G. Effects of digoxin and diltiazem upon ventricular ectopic activity and ventricular irregularity in atrial fibrillation, 220P
LEWIS, R. V. & MCDEVITT, D. G. The relative effects of digoxin and diltiazem upon ventricular ectopic activity in patients with chronic atrial fibrillation, 327
LEWIS, R. V. *see* CURRIE, D.
LEWIS, R. V., JACKSON, P. R. & RAMSAY, L. E. Exercise performance related to debrisoquine oxidation phenotype after single doses of metoprolol and atenolol, 630P
LIBERATI, R. *see* BRUNOZZI, L. T.
LIGHTMAN, S. *see* DUGGAN, J.
LI KAM WA, T. C., ALMOND, N. E., EDEKI, T., COOKE, E. D. & TURNER, P. Effect of captopril on skin blood flow following intradermal bradykinin measured by laser Doppler flowmetry, 659P
LIM, K. L. M. *see* HOLLAND, I. S.
LIMINANA, R. *see* VINCENT, J.
LINDBERG, R. *see* KALLIO, J.
LINDBERG, R. L. P. *see* PIHLAJAMÄKI, K. K.
LINDUP, W. E. *see* WOODHEAD, M. P.
LIPWORTH, B. J. & MCDEVITT, D. G. Airways, tremor and haemodynamic responses to inhaled salbutamol in normal subjects, 208P
LIPWORTH, B. J., CLARK, R. A., COUTIE, W., BROWN, R. A. & MCDEVITT, D. G. The biochemical effects of cumulative doses of inhaled salbutamol in normal subjects, 626P
LIPWORTH, B. J., CLARK, R. A., DHILLON, D. P., BROWN, R. A. & MCDEVITT, D. G. β-adrenoceptor responses to high doses of inhaled salbutamol in patients with bronchial asthma, 527
LITKA, P. *see* BROOM, C.
LITTLEY, M. D., HUTCHINGS, A., SPRAGG, B. P., ROUTLEDGE, P. A. & LAZARUS, J. H. The effect of throtoxicosis on isoniazid acetylation, 103
LLOYD, P. *see* DAVIS, S. S.
LOCKHART, A. *see* DINH XUAN, A. T.
LOEWEN, G. R., HERMAN, R. J., ROSS, S. G. & VERBEECK, R. K. Effect of dose on the glucuronidation and sulphation kinetics of diflunisal in man: single dose studies, 31

LOGAN, R. F. A. *see* BELL, G. D.
LONGMORE, J. *see* THEOFILOPOULOS, N.
LUCAS, R. A. *see* FEHER, M. D.
LUDWIG, E. A. *see* CERASA, L. A.
LUI, J. B. *see* TOMLINSON, B.
LUMLEY, P. *see* MACONOCHIE, J.
LUNELL, N.-O. *see* HARTMANN, D.
LUSCOMBE, D. K. *see* SALEK, M. S.
LYNAS, A. G. A., FITZPATRICK, K. T. J., BLACK, G. W., MIRAKHUR, R. K. & CLARKE, R. S. J. Influence of volatile anaesthetics on the potency of tubocurarine and atracurium, 617P

MACDONALD, T. M., COTTON, M. & PRESCOTT, L. F. Low dose dopamine in lithium poisoning, 195
MACLEAN, D. *see* LEWIS, R.
MACMAHON, D. *see* CROME, P.
MACONOCHIE, J., KENSINGTON, J. & LUMLEY, P. Evaluation of the vascular thromboxane A_2 receptor blocking activity of GR32191 in man, 662P
MACQUIN-MAVIER, I., ROUDOT-THOROVAL, F., CLERICI, C., GEORGE, C. & HARF, A. Comparative effects of bisoprolol and acebutolol in smokers with airway obstruction, 279
MADEJ, R. H., ELLIS, F. R. & TRING, I. A single dose pharmacokinetic study of two formulations of oral metoclopramide in the perioperative period, 221P
MADEJ, T. H., ELLIS, F. R. & TRING, I. A single dose pharmacokinetic study of Gastrobid Continus and Maxolon in the perioperative period, 747
MADEJ, T. H., SIMPSON, K. H., ABBOTT, P. & CARR, C. M. E. A placebo controlled study to assess the efficacy and acceptability of buccal prochlorperazine given perioperatively, 222P
MADEJ, T. H. *see* SIMPSON, K. H.
MAGGS, J. L., RILEY, R. J., LAMBERT, C., KITTERINGHAM, N. R. & PARK, B. K. The metabolism-dependent toxicity of phenytoin and sorbinil towards human leucocytes *in vitro*, 237P
MAGGS, J. L., *see* KITTERINGHAM, N. R.
MAGGS, J. L. *see* RILEY, R. J.
MALCOLM, S. L. *see* RODGERS, A.
MANI, V. *see* RILEY, S. A.
MANN, H. *see* GLADZIWA, U.
MANN, R. D. *see* BEM, J. L.
MANN, S. G. *see* COURTNEY, T. P.
MANNINEN, V. *see* KOSKINEN, P.
MANSEL, R. E. *see* HALLAM, A.
MARLEY, J. *see* CROME, P.
MARSHALL, I., AL-KAZWINI, S. J., HOLMAN, J. J. & CRAIG, R. K. Human-calcitonin gene-related peptide (CGRP) is a potent vasodilator in human mesenteric vasculature, 691
MARSHALL, R. W. *see* MERCER, A.
MATHUNA, P. M. *see* DAVIES, M. G.
MATHUNA, P. M. *see* O'REILLY, T.
MATRAN, R. *see* DINH XUAN, A. T.
MCALPINE, L. G. & THOMPSON, N. C. A double-blind placebo-controlled study of the effect of enalapril and indomethacin on bradykinin-induced wheal, 235P
MCAUSLANE, J. A. N., FREESTONE, S. & PRESCOTT, L. F. Concentration-dependent metabolism and renal clearance of *p*-aminohippurate, 621P
MCCAFFREY, P. M., RIDDELL, J. G., ARNOLD, J. M. O., NELSON, J. K. & MCDEVITT, D. G. Comparison of the effects of propranolol, metoprolol and ICI 118,551 on the CVS and finger tremor in hyperthyroidism, 675P
MCCLUSKER, M. *see* ROBERTS, N. M.
MCCOLLUM, P. T. *see* DAVIES, M. G.
MCDERMOTT, B. J., MCTAGGART, H. A., TAGGART, A. J., WILSON, G. & ROBERTS, S. D. Pharmacokinetics of benorylate in young volunteers and elderly patients with arthritis, 674P
MCDEVITT, D. G. *see* CURRIE, D.
MCDEVITT, D. G. *see* LEWIS, R.
MCDEVITT, D. G. *see* LEWIS, R. V.
MCDEVITT, D. G. *see* LIPWORTH, B. J.
MCDEVITT, D. G. *see* MCCAFFREY, P. M.
MCDEVITT, D. G. *see* NICHOLSON, A. N.
MCELNAY, J. C. *see* PASSMORE, C. M.
MCELNAY, J. S. *see* AL-FURAIH, T.
MCERLANE, B. *see* WRIGHT, M. R.
MCEWEN, J. *see* EDWARDS, A. A.
MCEWEN, J. *see* QURESHI, M. Z.
MCGEE, H., HICKEY, A., O'BOYLE, C., O'MALLEY, K. & JOYCE, C. R. B. Judgment analysis (JA) as a technique for providing individualized assessments of quality of life (QOL), 653P
MCGRATH, A. & FEELY, J. Patients' knowledge of and attitudes to medicines: an Irish perspective, 646P
MCHARDY, K. C. *see* SCOTT, A. K.
MCINNES, G. T. *see* MURDOCH, D. L.
MCKELLAR, J. *see* COATES, P.
MCKENNA, W. J. *see* JOHNSTON, A.
MCLEAN, S. *see* VERONESE, M. E.
MCMORLAND, G. H. *see* WRIGHT, M. R.
MCMURRAY, J. & STRUTHERS, A. C. Arginine vasopressin dissociates the diuresis and natriuresis due to atrial natriuretic factor in man, 214P
MCMURRAY, J. *see* LEWIS, R. V.
MCMURRAY, J. J. *see* SEIDELIN, P. H.
MCNABB, W. R., NOORMOHAMED, F. H. & LANT, A. F. Acute and long-term renal and metabolic effects of piretanide in congestive cardiac failure, 143
MCTAGGART, H. A. *see* MCDERMOTT, B. J.
MCVEIGH, G. E., GALLOWAY, D. B. & JOHNSTON, G. D. Antihypertensive efficacy and metabolic profile of low and conventional doses of cyclopenthiazide, 218P
MCVEIGH, G. E. & JOHNSTON, G. D. Comparison of the haemodynamic and hormonal effects of low and conventional dose cyclopenthiazide in normal volunteers, 634P
MEFFIN, P. J. *see* SALLUSTIO, B. C.
MEKKI, Q. A. & TURNER, P. Effect of ciclopolol on intraocular pressure in healthy volunteers, 89
MENICONI, L. *see* BRUNOZZI, L. T.
MERCER, A., ALLEN, E. A., MARSHALL, R. W. & RICHENS, A. The quantitative assessment of ethanol pharmacodynamics by eye movement analysis, 668P
MEREDITH, P. A. *see* DONNELLY, R.
MEREDITH, P. A. *see* SUMNER, D. J.
MEREDITH, P. A. *see* VINCENT, J.

MERKEL, C., GATTA, A., BOLOGNESI, M., PADRINI, R., FINUCCI, G. R., ANGELI, P. & RUOL, A. The calcium-channel blocker, verapamil, does not improve portal pressure in patients with alcoholic cirrhosis, 273
MESURE, R. *see* COLLIER, J.
MIDDLETON, E. JR *see* CERASA, L. A.
MILFERSTADT, S. *see* KIRCH, W.
MILLER, A. J. *see* COATES, P.
MILLER, W. R. *see* HALLAM, A.
MILLS, F. J. *see* DAVIES, D. S.
MILLSON, D. S., HARRY, J. D., HAWORTH, S. J. & WILKINSON, D. Effects of a 5-HT2 antagonist (ICI 169,369) on human pupillary responses, 625P
MILLSON, D. S., HARRY, J. D. & WILKINSON, D. Measurement of pupillary responses to miotic and mydriatic drugs in human volunteers, using a portable infrared pupillometer, 200P
MILNE, R. W., COULTHARD, K., NATION, R. L., PENNA, A. C., ROBERTS, G. & SANSOM, L. M. Lack of effect of erythomycin on the pharmacokinetics of single oral doses of phenytoin, 330
MINERS, J. *see* DAY, R. O.
MINERS, J. O. *see* DAY, R. O.
MIRAKHUR, R. K. *see* LYNAS, A. G. A.
MISZKIEL, K. A., BEASLEY, R. & HOLGATE, S. T. The influence of ipratropium bromide and sodium cromoglycate on benzalkonium chloride-induced bronchoconstriction in asthma, 295
MITCHELL, S. C. *see* AL-WAIZ, M.
MONKS, K. *see* ROBERTSON, D. R. C.
MOORE, D. J. *see* DAVIES, M. G.
MOORE, D. P. *see* GRAY, R. P.
MOORE, J. *see* DWYER, R.
MORDEN, A. *see* BELL, G. D.
MORELAND, T. A. *see* EDWARDS, A. A.
MORELAND, T. A. *see* QURESHI, M. Z.
MORGAN, D. J. *see* CAMPBELL, G. A.
MORIARTY, J. M. *see* O'CONNOR, P.
MORRISON-LACOMBE, G. *see* GIAUFRE, E.
MORTON, J. J. *see* MURDOCH, D. L.
MULPETER, K. *see* FEELY, J.
MURDOCH, D. L., MORTON, J. J., LECKIE, B., GILLAN, J., MURRAY, G. D., DAVIES, D. L. & MCINNES, G. T. Twice-daily low-dose captropil in diuretic-treated hypertensives, 215P
MURRAY, G. D. *see* MURDOCH, D. L.
MUSTAJOKI, P. *see* TOKOLA, O.
MUTCH, E. *see* WILLIAMS, F. M.
MYERS, M. *see* HARDY, B. G.

NAIDOO, D. *see* DAY, R. O.
NAKAMURA, K. *see* TANAKA, E.
NATION, R. L. *see* EVANS, A. M.
NATION, R. L. *see* MILNE, R. W.
NAYAK, V. K., KSHIRSAGAR, N. A., DESAI, N. K. & SATOSKAR, R. S. Influence of menstrual cycle on antipyrine pharmacokinetics in healthy Indian female volunteers, 604
NELSON, J. K. *see* MCCAFFREY, P. M.
NEWMAN, C. M. H. *see* WARREN, J. B.
NEWMAN, S. P. *see* SWINBURN, C. R.
NICHOLLS, D. P. *see* AL-FURAIH, T.
NICHOLLS, P. J. *see* HALLAM, A.
NICHOLLS, S. P. *see* TULLY, M. P.
NICHOLSON, A. N., WRIGHT, N. A., ZETLEIN, M. B., CURRIE, D. & MCDEVITT, D. G. Central effects of β-adrenoceptor antagonists II-Electroencephalogram and body sway, 129
NICHOLSON, A. N., PASCOE, P. A. & TURNER, C. Trimipramine and sleep in man, 201P
NICHOLSON, A. N. *see* CURRIE, D.
NICHOLSON, E. M. *see* WILLIAMS, F. M.
NICHOLSON, P. W. *see* CHEUNG, R.
NIMMO, W. S. *see* ROWBOTHAM, D. J.
NIVEN, A. A., GREVEL, J., AL-BANNA, M., KELLMAN, A. W., WHITING, B. & BRIGGS, J. D. Pharmacokinetics of cyclosporin in the early post-operative period following renal transplantation, 626P
NOEL, J. *see* KELLY, J. G.
NOORMOHAMED, F. H. *see* MCNABB, W. R.

O'BOYLE, C. *see* MCGEE, H.
O'BOYLE, C. A. Caffeine antagonism of the central effects of zopiclone and nitrazepam in man, 621P
O'BYRNE, S., O'CONNOR, P. & FEELY, J. Plasma protein binding of lignocaine and warfarin in non-insulin dependent diabetes mellitus, 648P
O'CONNOR, P., MORIARTY, J. M. & FEELY, J. Adverse drug reactions—incentives to enhance reporting, 616P
O'CONNOR, P. *see* FEELY, J.
O'CONNOR, P. *see* O'BYRNE, S.
O'DRISCOLL, K. *see* DAVIES, M. G.
O'FLYNN, M. *see* WEBB, D. J.
OGONOR, J. I. *see* ETTE, E. I.
OHNHAUS, E. E. *see* KIRCH, W.
OLLIER, S. *see* GOULD, C. A. L.
O'MALLEY, K. *see* DUGGAN, J.
O'MALLEY, K. *see* MCGEE, H.
O'NEILL, C. J. A. *see* CHEUNG, R.
ONGLEY, R. C. *see* WRIGHT, M. R.
O'NIELL, D., ROWAN, M. J., ABRAHAM, D., WALSH, J. B., COAKLEY, D. & FEELY, J. Role of the flash VEP in the diagnosis and assessment of elderly patients with mild to moderate Alzheimer's disease, 636P
O'REILLY, T., MATHUNA, P. M., KEELING, P. W. N., BARRY, M. & FEELY, J. Indocyanine green estimated liver blood flow in chronic liver disease: bolus *vs* steady-state infusion, 649P
ORD, R. A. *see* HOLLAND, I. S.
ORME, M. *see* WALLEY, T.
ORME, M.L'E. *see* EDWARDS, G.
OTTON, S. V. *see* CREWE, H. K.

PADRINI, R. *see* MERKEL, C.
PAGE, K. M. *see* EVANS, C. D.
PANDITA-GUNAWARDENA, N. D. *see* CROME, P.
PARK, B. K. & COLEMAN, J. W. The immunological basis of adverse drug reactions. A report on a Symposium held in Liverpool on 6th April 1988, 491
PARK, B. K. *see* CHRISTIE, G.
PARK, B. K. *see* KITTERINGHAM, N. R.
PARK, B. K. *see* LAMBERT, C.
PARK, B. K. *see* MAGGS, J. L.
PARK, B. K. *see* RILEY, R. J.

PARK, B. K. *see* TINGLE, M. D.
PARR, G. D. *see* DAVIS, S. S.
PASCOE, P. A. *see* NICHOLSON, A. N.
PASSMORE, C. M., MCELNAY, J. C., RAINEY, E. A. & D'ARCY, P. F. Metronidazole excretion in human milk and its effect on the suckling neonate, 45
PATSALOS, P. N., DUNCAN, J. S. & SHORVON, S. D. Effect of the removal of individual antiepileptic drugs on antipyrine kinetics, in patients taking polytherapy, 253
PATSALOS, P. N. & ZAKRZEWSKA, J. M. Oxcarbazepine in the management of intractable trigeminal neuralgia, 641P
PAULL, P. D. *see* DAY, R. O.
PEAKER, S. *see* KUMAR, S.
PEAKER, S. *see* PENN, N. D.
PECK, A. W. *see* YUEN, W. C.
PELKONEN, O. *see* ARVELAJ, P.
PENN, N. D., FEELY, M., PEAKER, S., GRIFFITHS, A. P. & TINDALL, H. Use of a pharmacological indicator (low-dose phenobarbitone) and TSH levels to monitor compliance with thyroxine, 205P
PENNA, A. C. *see* MILNE, R. W.
PERELMAN, M. S. *see* TIONG, T. H.
PEUCH, A. J. *see* DANJOU, P.
PHILPOTT, R. M. *see* GEORGE, A. J.
PICKLES, H. *see* CASTLEDEN, C. M.
PIEPER, J. A. *see* LALONDE, R. L.
PIHLAJAMÄKI, K. K., LINDBERG, R. L. P. & JANTUNEN, M. E. Lack of effect of cimetidine on the pharmacokinetics of bupivacaine in healthy subjects, 403
PINAUD, M. *see* LE NORMAND, Y.
PINHAS, H. *see* BRUNO, R.
PIPER, P. J. *see* EVANS, J. M.
PIXLEY, F. J. *see* WARREN, J. B.
POLLAK, P. T., SHARMA, A. D. & CARRUTHERS, S. G. Correlation of amiodarone dosage, QT interval and corneal microdeposits with serum desethylamiodarone concentration, 217P
PONIATOWSKA, T. J. *see* PRICHARD, P. J.
POZUELO, M. *see* DUEÑAS-LAITA, A.
PREADY, N. *see* BROOM, C.
PRESCOTT, L. F. *see* MACDONALD, T. M.
PRESCOTT, L. F. *see* MCAUSLANE, J. A. N.
PRESCOTT, L. F. *see* SPEIRS, G. C.
PRESTON, S. J., ARNOLD, M. H., BELLER, E. M., BROOKS, P. M. & BUCHANAN, W. W. Variability in response to nonsteroidal anti-inflammatory analgesics: evidence from controlled clinical therapeutic trial of flurbiprofen in rheumatoid arthritis, 759
PRESTON, D. J. *see* ARNOLD, M. H.
PRICE, J. D. E. *see* WRIGHT, M. R.
PRICHARD, B. N. C. *see* RENONDIN, J. C.
PRICHARD, B. N. C. *see* TOMLINSON, B.
PRICHARD, P. J., PONIATOWSKA, T. J., WILLARS, J. E., RAVENSCROFT, A. T. & HAWKEY, C. J. Effect in man of aspirin, standard indomethacin, and sustained release indomethacin preparations on gastric bleeding, 167
PULLAR, T. *see* FEELY, M.
PURBA, H. S. & BACK, D. J. Inhibition of tolbutamide 4-hydroxylase activity in human liver microsomes by benzodiazepines, 227P
PURDIE, Y. J. *see* SALLUSTIO, B. C.
QURESHI, M. Z., MORELAND, T. A., DURNIN, C. J. & MCEWEN, J. Influence of the timing of glipizide dosage on post-prandial hypoglycaemia in healthy volunteers, 673P
RAINEY, E. A. *see* PASSMORE, C. M.
RAMSAY, L. E. *see* CAMERON, H. A.
RAMSAY, L. E. *see* LEWIS, R. V.
RANCE, D. J. *see* COLLIER, J.
RANE, A. *see* HARTMANN, D.
RAVENSCROFT, A. T. *see* PRICHARD, P. J.
RAVINDRAN, A. V. *see* GEORGE, A. J.
RAWLINS, M. D. Spontaneous reporting of adverse drug reactions I: The data, 1
RAWLINS, M. D. Spontaneous reporting of adverse drug reactions II: Uses, 7
RAWLINS, M. D. *see* BATEMAN, D. N.
RAWLINS, M. D. *see* BEM, J. L.
RAWLINS, M. D. *see* FERNER, R. E.
RAWLINS, M. D. *see* ISAH, A. G.
RAWLINS, M. D. *see* WILLIAMS, F. M.
REEVES, P. T., HANRAHAN, P., EDELMAN, J. & ILETT, K. F. Effect of intra-articular glucocorticoids on the disposition of sulphadimidine in chronic osteoarthritis patients, 563
REGNARD, J. *see* DINH XUAN, A. T.
REID, J. L. *see* DONNELLY, R.
REID, J. L. *see* HOGG, K. J.
REID, J. L. *see* LEES, K. R.
REID, J. L. *see* TSAI, H. H.
REID, J. L. *see* VINCENT, J.
RENONDIN, J. C., TOMLINSON, B., GRAHAM, B. R. & PRICHARD, B. N. C. Urapidil, α- and β-adrenoceptor blocking activity in healthy volunteers, 216P
RENONDIN, J. C. *see* TOMLINSON, B.
RENWICK, A. G. *see* ROBERTSON, D. R. C.
REUBI, F. C. *see* DAVIES, B. E.
RIBEYROL, M. *see* LE NORMAND, Y.
RICHENS, A. *see* ALLEN, E.
RICHENS, A. *see* MERCER, A.
RIDDELL, J. G. *see* COPELAND, S.
RIDDELL, J. G. *see* MCCAFFREY, P. M.
RILEY, R. J., LAMBERT, C., MAGGS, J. L., KITTERINGHAM, N. R. & PARK, B. K. An investigation of the relationship between the metabolism and cytotoxicity of mianserin *in vitro*, 238P
RILEY, R. J., MAGGS, J. L., LAMBERT, C., KITTERINGHAM, N. R. & PARK, B. K. An *in vitro* study of the microsomal metabolism and cellular toxicity of phenytoin, sorbinil and mianserin, 577
RILEY, R. J., ROBERTS, P., KITTERINGHAM, N. R. & PARK, B. K. The effect of hepatic enzyme induction on the *in vitro* cytotoxicity of phenytoin and mianserin, 666P
RILEY, R. J. *see* MAGGS, J. L.
RILEY, S. A., TAVARES, I. A., BENNETT, A. & MANI, V. Delayed-release mesalazine (5-aminosalicylic acid): coat dissolution and excretion in ileostomy subjects, 173
RILEY, S. A. *see* SUTCLIFFE, F. A.
ROATH, O. S. *see* CHALLENOR, V. F.
ROBERTS, B. E. *see* KUMAR, S.
ROBERTS, G. *see* MILNE, R. W.
ROBERTS, N. M., MCCLUSTER, M., CHUNG, K. F. &

BARNES, P. J. Effect of a PAF antagonist, BN52063, on PAF-induced bronchoconstriction in normal subjects, 65
ROBERTS, P. *see* RILEY, R. J.
ROBERTS, S. D. *see* MCDERMOTT, B. J.
ROBERTSON, D. R. C., WOOD, N., MONKS, K., WALLER, D. G., RENWICK, A. G. & GEORGE, C. F. The effect of age on the pharmacokinetics of levodopa, 619P
ROBINSON, K. *see* JOHNSTON, A.
ROCHER, I. *see* KIRCH, W.
RODGERS, A., MALCOLM, S. L., BLACKBURN, N. A., WOODHOUSE, K. W. & BATEMAN, D. N. A kinetic study of sustained release Madopar in elderly patients after day and night-time dosing, 219P
ROSS, S. G. *see* LOEWEN, G. R.
ROUDOT-THORAVAL, F. *see* MACQUIN-MAVIER, I.
ROUSSET-ROUVIERE, B. *see* GIAUFRE, E.
ROUTLEDGE, P. A. Clinical pharmacology and the art of bespoke prescribing, 339
ROUTLEDGE, P. A. *see* LITTLEY, M. D.
ROWMAN, M. J. *see* DAVIES, M. G.
ROWAN, M. J. *see* O'NIELL, D.
ROWBOTHAM, D. J., BAMBER, P. A. & NIMMO, W. S. Comparison of the effect of cisapride and metoclopramide on morphine-induced delay in gastric emptying, 741
ROWLAND, M. *see* SUTCLIFFE, F. A.
RUOL, A. *see* MERKEL, C.
RURAK, D. W. *see* WRIGHT, M. R.
RYLANCE, G. W. *see* HOUTMAN, P. N.
RYLANCE, G. W. *see* WOODS, C. G.

SAARIALHO-KERE, U. Psychomotor, respiratory and neuroendocrinological effects of nalbuphine and haloperidol, alone and in combination, in healthy subjects, 79
SALEH, S., JOHNSTON, A., EDEKI, T. I. & TURNER, P. Tolerance and kinetic study of intravenous medifoxamine in healthy human volunteers, 645P
SALEK, M. S., LUSCOMBE, D. K., WALKER, S. R., GROB, P. R., VANDENBURG, M. J. & LEWIS, M. J. Cardiovascular disease and quality of life, 628P
SALLUSTIO, B. C., PURDIE, Y. J., WHITEHEAD, A. G., AHERN, M. J. & MEFFIN, P. J. The disposition of ketoprofen enantiomers in man, 765
SANGER, G. J. *see* BURKE, T. A.
SANSOM, L. N. *see* EVANS, A. M.
SANSOM, L. M. *see* MILNE, R. W.
SAPRA, M. *see* GREEN, K. L.
SATOSKAR, R. S. *see* NAYAK, V. K.
SAVDIE, E. *see* DAY, R. O.
SAVLIWALA, M. *see* CERASA, L. A.
SCHELLENS, J. H. M., VAN DER WART, J. H. F., DANHOF, M., VAN DER VELDE, E. A. & BREIMER, D. D. Relationship between the metabolism of antipyrine, hexobarbitone and theophylline in man as assessed by a 'cocktail' approach, 373
SCHMITT, H. *see* GLADZIWA, U.
SCHWARTZ, J. I. *see* BACHMANN, K.
SCIBERRAS, D. G., BOLOGNESE, J. A., WILSON, S., JAMES, I. & BABER, S. Histamine mediation of the inflammatory responses to intradermally injected platelet activating factor, 209P
SCOTT, A. K., CAMERON, G. A., KHIR, A. S. M., MCHARDY, K. C. & HAWKSWORTH, G. M. Oxazepam elimination in patients with diabetes mellitus, 224P
SCOTT, M. G. *see* AL-FURAIH, T.
SCOTT, M. G. *see* TULLY, M. P.
SEAL, D. *see* CHEUNG, R.
SEIDELIN, P. H., MCMURRAY, J. J., BROWN, R. A. & STRUTHERS, A. D. The effect of angiotensin II and noradrenaline on sodium excretion in man, 203P
SEIDELIN, P. H., BENJAMIN, N., STRUTHERS, A. D. & WEBB, D. J. Augmentation of sympathetic vasoconstriction in forearm resistance vessels by angiotensin II in man, 210P
SESARDIC, D., BOOBIS, A. R., EDWARDS, R. J. & DAVIES, D. S. A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the *O*-deethylation of phenacetin and is inducible by cigarette smoking, 363
SEVER, P. S. *see* FEHER, M. D.
SEYMOUR, R. A. *see* HOLLAND, I. S.
SHANIK, G. D. *see* DAVIES, M. G.
SHANKS, R. G. *see* COPELAND, S.
SHANKS, R. G. *see* GILL, T. S.
SHARMA, A. D. *see* POLLACK, P. T.
SHARMA, S. K. *see* ZEZULKA, A. V.
SHAW, R. W. *see* COURTNEY, T. P.
SHAWKET, S. *see* TAN, K. K. C.
SHEIKH, A. S. & SURIA, A. Ability of human plasma to inhibit platelet aggregation in asthma, 226P
SHERIDAN, D. J. *see* DIXON, M. S.
SHERIDAN, D. J. *see* THOMAS, P.
SHINEBOURNE, E. A. *see* JOHNSTON, A.
SHORT, A. H. *see* DAVIS, S. S.
SHORVON, S. D. *see* PATSALOS, P. N.
SHUSTER, S. Topical indomethacin and psoriasis—a reply, 119
SILAS, J. H. *see* LENNARD, M. S.
SILKE, B. *see* ZEZULKA, A. V.
SIMPSON, K. H., MADEJ, T. H., TRING, I., CARR, C. M. E., ABBOTT, P. & ELLIS, F. R. Evaluation of different formulations of buccal morphine, 223P
SIMPSON, K. H. *see* MADEJ, T. H.
SLAUGHTER, R. L. *see* CERASA, L. A.
SLAUGHTER, R. L. *see* WOODING-SCOTT, R. A.
SMALLEY, J. *see* WOODING-SCOTT, R. A.
SMART, W. *see* GLOVER, D. R.
SMITH, D. L. *see* LEENEN, F. H. H.
SMITH, H. J. *see* HALLAM, A.
SMITH, R. L. *see* AL-WAIZ, M.
SMITH, R. L. *see* CHOLERTON, S.
SMITH, R. L. *see* HAGUE, D.
SOMOGYI, A. *see* CHEN, Z. R.
SOMOGYI, A. A. *see* EVANS, A. M.
SPARROW, P. *see* BROOM, G.
SPEIRS, G. C., CRITCHLEY, J. A. J. H., TEMPLE, R. M., WINNEY, R. J. & PRESCOTT, L. F. Retention of paracetamol metabolites in chronic renal failure, 204P
SPENCE, V. A. *see* KHAN, F.
SPRAGG, B. P. *see* LITTLEY, M. D.
STAIGER, C. H. *see* TINGLE, M. D.
STANFORD, C. F. *see* AL-FURAIH, T.
STANFORD, C. F. *see* TULLY, M. P.

STEVENS, J. *see* TAYLOR, K. M. G.
STRAKA, R. J. *see* LALONDE, R. L.
STRUTHERS, A. D. & KHAN, F. The sympathetic control of skin microvascular tone: studies with Laser Doppler flowmetry, 206P
STRUTHERS, A. D. *see* KHAN, F.
STRUTHERS, A. D. *see* MCMURRAY, J.
STRUTHERS, A. D. *see* SEIDELIN, P. H.
STURN, B. *see* IMBIMBO, B. P.
SULLENS, C. M. *see* CHEUNG, R.
SUMNER, D. J., MEREDITH, P. A., HOWIE, C. A. & ELLIOTT, H. L. Initial blood pressure as a predictor of the response to antihypertensive therapy, 715
SUMNER, D. J. *see* VINCENT, J.
SURIA, A. *see* SHEIKH, A. S.
SUTCLIFFE, F. A., RILEY, S. A., KASER-LIARD, B., TURNBERG, L. A. & ROWLAND, M. Absorption of drugs from the human jejunum and ileum, 206P
SWANSON, B. R. *see* DAY, R. O.
SWINBURN, C. R., WAKEFIELD, J. M., NEWMAN, S. P. & JONES, P. W. Evidence of prednisolone induced mood change ('steroid euphoria') in patients with chronic obstructive airways disease, 709
SZABADI, E. *see* THEOFILOPOULOS, N.

TAGGART, A. J. *see* MCDERMOTT, B. J.
TAM, Y. K. *see* WRIGHT, M. R.
TAN, K. K. C., TRULL, A. K. & SHAWKET, S. Study of the potential pharmacokinetic interaction between ciprofloxacin and cyclosporin in man, 644P
TANAKA, E. & NAKAMURA, E. Effects of H_2-receptor antagonists on ethanol metabolism in Japanese volunteers, 96
TASKER, T. C. G. *see* GILL, T. S.
TAVARES, I. A. *see* RILEY, S. A.
TAYLOR, G. *see* TAYLOR, K. M. G.
TAYLOR, K. M. G., TAYLOR, G., KELLAWAY, I. W. & STEVENS, J. The pharmacokinetics of sodium cromoglycate following inhalation of free and liposomal cromoglycate by human volunteers, 207P
TAYLOR, S. H. *see* ZEZULKA, A. V.
TEMPLE, R. M. *see* SPEIRS, G. C.
TENERO, D. M. *see* LALONDE, R. L.
TETT, S. E., CUTLER, D. J., DAY, R. O. & BROWN, K. F. A dose-ranging study of the pharmacokinetics of hydroxychloroquine following intravenous administration to healthy volunteers, 303
THE CANADIAN FELODIPINE STUDY GROUP Antihypertensive efficacy of the calcium antagonist felodipine in patients with persisting hypertension on β-adrenoceptor blocker therapy, 535
THEOFILOPOULOS, N., LONGMORE, J., KERR, F. A., SZABADI, E. & BRADSHAW, C. M. Consensual pupillary responses to mydriatic and miotic drugs, 697
THIEME, G. *see* IMBIMBO, B. P.
THOMAS, P. & SHERIDAN, D. J. Acute and chronic haemodynamic effects of nicardipine in patients with congestive heart failure, 243P
THOMAS, P. *see* DIXON, M. S.
THOMSON, A. H. & WHITING, B. The population pharmacokinetics of lisinopril in hypertensive patients, 618P
THOMSON, N. C. *see* MCALPINE, L. G.
THOMSON, A. *see* HOGG, K. J.
TIJA, J. F. *see* BACK, D. J.
TILL, J. A. *see* JOHNSTON, A.
TINDALL, H. *see* FEELY, M.
TINDALL, H. *see* PENN, N. D.
TINGLE, M. D., LAVENS, S. E., STAIGER, C. H. & PARK, B. K. Metabolism of ciamexon by human liver microsomes, 667P
TIONG, T. H., HUNG, S. O. & PERELMAN, M. S. Penetration of nadolol into aqueous humour after a single oral dose, 92
TOKOLA, O., MUSTAJOKI, P. & HIMBERG, J-J. Haem arginate improves hepatic oxidative metabolism in varigate porphyria, 753
TOMLINSON, B., CRUICKSHANK, J. M., HAYES, Y., RENONDIN, J. C., LUI, J. B., GRAHAM, B. R. & PRICHARD, B. N. C. Effects of pindolol and xamoterol on plasma creatine kinase in healthy subjects, 631P
TOMLINSON, B. *see* RENONDIN, J. C.
TRING, I. *see* MADEJ, T. H.
TRING, I. *see* SIMPSON, K. H.
TRULL, A. K. *see* TAN, K. C. C.
TSAI, H. H., LEES, K. R., HOWDEN, C. W. & REID, J. L. The pharmacokinetics and pharmacodynamics of perindopril in patients with hepatic cirrhosis, 212P
TUCKER, G. T. *see* CREWE, H. K.
TUCKER, G. T. *see* JACKSON, P. R.
TUCKER, G. T. *see* LENNARD, M. S.
TULLY, M. P., ELBORN, J. S., NICHOLLS, D. P., SCOTT, M. G. & STANFORD, C. F. Acute effects of diuretics in heart failure, 642P
TURNBERG, L. A. *see* SUTCLIFFE, F. A.
TURNER, C. *see* NICHOLSON, A. N.
TURNER, P. *see* AL-SEREITI, M. R.
TURNER, P. *see* EDEKI, T. I.
TURNER, P. *see* JACKSON, S. H. D.
TURNER, P. *see* LI KAM WA, T. C.
TURNER, P. *see* MEKKI, Q. A.
TURNER, P. *see* SALEH, S.

UECKERT, B. *see* IMBIMBO, B. P.
UNGER, W. P. *see* LEENEN, F. H. H.
UPWARD, J. W., EDWARDS, J. G., GOLDIE, A. & WALLER, D. G. Comparative effects of fluoxetine and amitriptyline on cardiac function, 399
URSO, R. *see* IMBIMBO, B. P.

VANDENBURG, M. J. *see* SALEK, M. S.
VAN DER BOON, M. J. V. *see* JONKMAN, J. H. G.
VAN DER VELDE, E. A. *see* SCHELLENS, J. H. M.
VAN DER WART, J. H. F. *see* SCHELLENS, J. H. M.
VERBEECK, R. K. *see* LOEWEN, G. R.
VERMA, S. P. *see* ZEZULKA, A. V.
VERONESE, M. E., MCLEAN, S. & HENDRIKS, R. Plasma protein binding of amiodarone in a patient population: measurement by erythrocyte partitioning and a novel glass-binding method, 721
VIDI, A. *see* IMBIMBO, B. P.
VINCENT, J., LIMINANA, R., MEREDITH, P. A. & REID, J. L. The pharmacokinetics, anti-histamine and concentration-effect relationship of ebastine in healthy subjects, 497

VINCENT, J., SUMNER, D. J. & REID, J. L. Ebastine: the effect of a new antihistamine on psychomotor performance and autonomic responses in healthy subjects, 503
VISCO, J. *see* WOODING-SCOTT, R. A.
VITOU, P. *see* DINH XUAN, A. T.

WADE, D. N. *see* DAY, R. O.
WAINER, I. W. *see* LALONDE, R. L.
WAKEFIELD, J. M. *see* SWINBURN, C. R.
WALKER, S. M. *see* DAVIS, S. S.
WALKER, S. R. *see* SALEK, M. S.
WALLER, D. G. *see* CHALLENOR, V. F.
WALLER, D. G. *see* ROBERTSON, D. R. C.
WALLER, D. G. *see* UPWARD, J. W.
WALLER, P. C. *see* CAMERON, H. A.
WALLEY, T., WINSTANLEY, P., WINTER, T., ORME, M. & BRECKENRIDGE, A. Effects of captopril on renal function in a hypertensive population, 619P
WALLEY, T., WOODS, K. & BARNETT, D. Effects of intravenous and oral nifedipine on *ex vivo* platelet function, 651P
WALLEY, T. J., WOODS, K. L. & BARNETT, D. B. Effects of calcium channel blockers on *in vitro* platelet function in whole blood using single platelet counting, 652P
WALLIS, C. *see* HOGAN, J. C.
WALSH, J. B. *see* O'NIELL, D.
WALSH, M. J. *see* GRAY, R. P.
WALTERS, G. E. *see* WHITEHEAD, E. M.
WARD, C. *see* FERNER, R. E.
WARD, D. E. *see* JOHNSTON, A.
WARD, M. J. *see* ALI, N. J.
WARD-BOOTH, R. P. *see* HOLLAND, I. S.
WAROT, D. *see* DANJOU, P.
WARREN, J. B., FULLER, R. W., DOLLERY, C. T., WILLIAMS, V. C. & GERTZ, B. J. Assessment of L-657, 743 (MK-912), an α_2-adrenoceptor antagonist, using intravenous clonidine in man, 627P
WARREN, J. B., NEWMAN, C. M. H., PIXLEY, F. J., FULLER, R. W. & DOLLERY, C. T. The importance of bradykinin and histamine in the skin response to antigen, 803
WARRINGTON, S. J., WEERASURIYA, K. & BURGESS, C. D. Correction of systolic time intervals for heart rate: A comparison of individual with population derived regression equations, 155
WASHINGTON, N. *see* DAVIS, S. S.
WASSERMAN, M. *see* BROOM, C.
WATSON BUCHANAN, W. *see* ARNOLD, M. H.
WATSON BUCHANAN, W. *see* PRESTON, S. J.
WEBB, D. *see* BENJAMIN, D.
WEBB, D. J., BENJAMIN, N., ALLEN, M. J., BROWN, J., O'FLYNN, M. & COCKCROFT, J. R. Vascular responses to local atrial natriuretic peptide infusion in man, 245
WEBB, D. J. *see* SEIDELIN, P. H.
WEERASURIYA, K. *see* WARRINGTON, S. J.
WEIR, D. G. *see* DAVIES, M. G.
WELBURN, P. J. *see* DAVIES, D. S.
WELLSTEIN, A. *see* BELZ, G. G.
WHITE, A. S. T. *see* CROME, P.
WHITE, A. S. T. *see* FLANAGAN, R. J.
WHITEHEAD, A. *see* DAY, R. O.
WHITEHEAD, A. G. *see* SALLUSTIO, B. C.
WHITEHEAD, E. M., WALTERS, G. E., WILLIAMS, P. E. O. & JOHNSTON, G. D. Pharmacokinetics of cilazaprilat in healthy volunteers, 239P
WHITEHEAD, T. *see* DAY, R. O.
WHITEHEAD, T. M. *see* GILL, T. S.
WHITING, B. *see* NIVEN, A. A.
WHITING, B. *see* THOMSON, A. H.
WIEGAND, U. W. *see* BELZ, G. G.
WILKINSON, D. *see* MILLSON, D. S.
WILLARS, J. E. *see* PRICHARD, P. J.
WILLIAMS, F. M., NICHOLSON, E. M., MUTCH, E., WYNNE, H., WRIGHT, P. & RAWLINS, M. D. Human liver and plasma aspirin esterase, 229P
WILLIAMS, J. *see* ALLEN, E.
WILLIAMS, K. M. *see* DAY, R. O.
WILLIAMS, P. E. O. *see* WHITEHEAD, E. M.
WILLIAMS, V. C. *see* WARREN, J. B.
WILSON, G. *see* MCDERMOTT, B. J.
WILSON, S. *see* SCIBERRAS, D. G.
WINNEY, R. J. *see* SPEIRS, G. C.
WINSTANLEY, P. *see* WALLEY, T.
WINSTANLEY, P. A. & COLEMAN, J. W. Effects of antimalarial drugs on the growth of granulocyte-monocyte colonies in cultures of normal human bone marrow, 660P
WINTER, T. *see* WALLEY, T.
WINTERTON, S. J. *see* DIXON, M. S.
WOOD, N. *see* ROBERTSON, D. R. C.
WOODHEAD, M. P. & LINDUP, W. E. Uraemic binding inhibitors and the bromocresol purple assay for albumin, 229P
WOODHOUSE, K. W. *see* RODGERS, A.
WOODING-SCOTT, R. A., SMALLEY, J., VISCO, J. & SLAUGHTER, R. L. The pharmacokinetics and pharmacodynamics of quinidine and 3-hydroxy-quinidine, 415
WOODS, G. C., LAMB, R. & RYLANCE, G. W. The use of intravenous ranitidine in stressed children, 671P
WOODS, H. F. *see* CREWE, H. K.
WOODS, H. F. *see* JACKSON, P. R.
WOODS, H. F. *see* LENNARD, M. S.
WOODS, K. *see* WALLEY, T.
WOODS, K. L. *see* WALLEY, T. J.
WOOLLARD, R. *see* JACKSON, S. H. D.
WRIGHT, M. R., AXELSON, J. E., RURAK, D. W., MCERLANE, B. MCMORLAND, G. H., ONGLEY, R. C., TAM, Y. K. & PRICE, J. D. E. Linearity of metoclopramide kinetics at doses of 5–20 mg, 469
WRIGHT, M. R., AXELSON, J. E., RURAK, D. W., MCERLANE, B., MCMORLAND, G. H., ONGLEY, R. C., TAM, Y. K. & PRICE, J. D. E. Effect of haemodialysis on metoclopramide kinetics in patients with severe renal failure, 474
WRIGHT, N. A. *see* CURRIE, D.
WRIGHT, N. A. *see* NICHOLSON, A. N.
WRIGHT, P. *see* WILLIAMS, F. M.
WYLD, P. J. *see* BURNS, E.
WYNNE, H. *see* WILLIAMS, F. M.

YEANG, Y. *see* HOGAN, J. C.
YUEN, W. C. & PECK, A. W. Lamotrigine pharmacokinetics: oral and i.v. infusion in man, 242P

ZAKRZEWSKA, J. M. *see* PATSALOS, P. N.
ZAKRZEWSKI, J. T. *see* EVANS, J. M.
ZETLEIN, M. B. *see* NICHOLSON, A. N.
ZEZULKA, A. V., SILKE, B., VERMA, S. P., SHARMA, S. K., JACKSON, N. C. & TAYLOR, S. H. The influence of patients' posture on vasodilator haemodynamics, 238P
ZUANETTI, G. *see* BRUNOZZI, L. T.

SUBJECT INDEX

(P = proceedings)

Absolute bioavailability, 469
Absorption, 206P
Acebutolol, 279
ACE inhibitors, 547
Acetaldehyde, 96
Acetylation, 103, 563
Acupressure, 225P
α-adrenoceptor activity, 216P
α-adrenoceptor blockers, 267
α-adrenoceptors, 733
α_2-adrenoceptors, 703
α_2-adrenoceptor antagonist, 627P
Adverse drug reactions, 1, 7, 347, 491, 616P
Adverse reactions, 679
Age, 211P, 535, 619P, 629P, 653P, 660P, 674P
AIDS, 487
Airway obstruction, 279
Airway responsiveness, 515
Albumin, 229P
Allopurinol, 423, 429, 649P
Alzheimer's disease, 636P
5-aminosalicylic acid, 173
Amioderone, 217P, 671P, 721
Amodiaquine, 624P
Amoxicillin, 385
Anaesthetic, 187, 617P
Analgesics, 759
Anaphylaxis, 509
Angiotensin I, 547
Angiotensin II, 203P, 210P, 629P
Angiotensin converting enzyme inhibition, 478
Anti-allergic effects, 664P
Anti-arrhythmic, 672P
Antibodies, 624P
Anticholinergic effects, 607
Anticonvulsant levels, 233P
Antidepressants, 399
Antiepileptic drug, 242P, 253
Antihistamine, 113, 497, 503, 509
Antihypertensive response, 61
Antihypertensive therapy, 715
Antimalarial drugs, 660P
Antipyrine, 373, 604, 657P, 753, 808
Antipyrine kinetics, 253
Apomorphine, 733
Arginine vasopressin, 214P
Aromatase, 663P
Arrhythmias, 489
Arterioles, 245
Arthritis, 488, 674P
Atrial natriuretic factor, 797
Aspirin, 167, 455, 463
Aspirin esterase, 229P
Asthma, 226P, 295, 515, 527, 703
Atenolol, 53, 121, 213P, 630P, 800
Atracurium, 617P
Atrial fibrillation, 213P, 220P, 327
Atrial natriuretic factor, 214P
Atrial natriuretic peptide, 245, 629P
Autonomic nervous system, 503
Azelastine, 515

β-adrenoceptor, 527
β-adrenoceptor activity, 216P
β-adrenoceptor agonist, 228P
β-adrenoceptor antagonists, 121, 129, 547
β_1-adrenoceptor selectivity, 279
Baldness, 481
Baroreceptor reflex activity, 547
Beclamethasone, 634P
Benorylate, 674P
Benzalkonium chloride, 295
Benzodiazepines, 227P
Bioavailability, 225P
Biochemical effects, 626P
Biperiden, 664P
Bisoprolol, 53, 279
Bleeding, 167
Blood flow, 245
Blood pressure, 547, 715
Blood purification, 315
BN 52063, 65
Body sway, 129
Bone resorption, 634P
Bradykinin, 113, 235P, 659P, 803
Breast carcinoma, 663P
Breast milk, 183, 639P
BRL 24924, 261
BRL-37344, 228P
Bronchial hyperreactivity, 703
Bronchoconstriction, 65, 295, 509
Buccal absorption, 656P
Buccal administration, 222P, 223P
Bupivacaine, 403

Caffeine, 621P
Calcitonin gene related peptide, 691
Calcium, 653P
Calcium antagonist, 183, 535
Calcium channel blockers, 652P
Captopril, 215P, 619P, 656P, 659P
Carbimazole, 652P
Cardiac failure, 143
Cardiovascular, 155
Cardiovascular disease, 628P
Cardiovascular effects, 481, 607
Cardiovascular response, 232P
Caudal anaesthesia, 116
Cephalexin, 391
Children, 216P
Chloroquine, 179
Cholinergic mechanisms, 261
Chronic airflow limitation, 709
Chronopharmacokinetics, 285

Chronopharmacology, 73, 613
Ciamexon, 667P
Cicloprolol, 89
Cigarette smoking, 363
Cilazaprilat, 239P
Cimetidine, 403
Ciprofloxacin, 191, 644P
Circadian variation, 73
Cirrhosis, 212P
Cisapride, 741, 808
Clavulanic acid, 385
Clearance, 187, 191, 334
Clinical judgement analysis, 355
Clinical significance, 355
Clinical trials, 355, 661P
Clonidine, 627P, 703
CNS effects, 607
Cocktail approach, 373
Committee on Safety of Medicines, 679
Compliance, 205P, 391, 616P, 620P, 641P, 661P
Concentration-effect, 61, 497
Concentration-effect analysis, 715
Congestive heart failure, 243P
Coproxamol, 220P, 660P
Corneal microdeposits, 217P
Corticosteroids, 334, 709
Creatine kinase, 631P
Cromokalim, 227P, 640P, 658P
CT scans, 721
Cure, 391
Cyclooxygenase inhibition, 113
Cyclopenthiazide, 218P, 634P
Cyclosporin, 626P, 644P
Cytochrome P-450, 236P, 373
Cytochrome P-450d, 363
Cytotoxicity, 238P

D_2-receptor antagonist, 654P
Dapsone, 487
Data interpretation, 771
Debrisoquine, 601, 791
Debrisoquine oxidation, 630P
Delayed release, 173
Dementia, 202P
Depression, 202P
Desethylchloroquine, 303
Desethylhydroxychloroquine, 303
Desipramine, 638P
Dextropropoxyphene, 660P
Diabetes mellitus, 224P, 648P
Diazepam, 116, 595
Diflunisal, 31
Digoxin, 220P, 327, 644P, 657P
Diltiazem, 220P, 327
Diuresis, 214P
Diuretics, 143, 642P
Dopamine, 195, 654P, 733
Dorsal hand vein, 797
Dose-concentration response, 429
Dose-dependence, 303
Dose-linearity, 469
Dose-response, 423
Drug disposition, 771
Drug interaction, 96, 253, 334, 455, 800
Drug metabolism, 753
Drug monitoring, 233P
Drug prescriptions, 347
Drug therapy, 622P

Ebastine, 497
Elderly, 210P, 219P, 323, 347, 613, 673P, 787
Electrocardiogram, 399
Electroencephalogram, 129
Elimination kinetics, 187
ELISA, 624P
Enalapril, 235P, 632P, 781, 803
Enalaprilat, 781
Enantiomers, 100, 227P, 623P, 655P, 658P, 676P, 765, 771
Endoscopy, 595
Enzyme induction, 253, 363, 666P, 808
Enzyme inhibition, 649P, 808
Epidural anaesthesia, 635P
Erythromycin, 330
Ethanol, 96, 668P, 676P
Eudragit S, 173
Euphoria, 709
Event related potentials, 674P
Exercise testing, 569
Extrapyramidal reactions, 201P
Eye movement, 668P

Famotidine, 315, 639P
Felodipine, 535, 557, 644P
Fenoterol, 676P
Flare, 113
Flecainide, 216P
Flowmeters, 267
Flurazepam, 673P
Flurbiprofen, 759
Forearm blood flow, 633P
Frusemide, 143

Gamma scintigraphy, 435
Gastric emptying, 741
Gastric mucosa, 167
Gastrobid Continus, 747
Gastrointestinal tract, 261
GC-MS assay, 227P
Genetic polymorphism, 230P, 231P, 807
Glipizide, 240P, 673P
Glucocorticoid, 563
Glucuronidation, 31
GR32191, 662P

H_1-receptor, 509
H_1-receptor antagonist, 515
H_2-receptor antagonist, 96, 315
Haem arginate, 753
Haemodialysis, 385, 474, 781
Haemodynamics, 589
Haemodynamic effects, 634P
Haloperidol, 79
Healthy volunteers, 179
Heart failure, 642P, 644P, 669P
Heart rate, 155
Hepatic encephalopathy, 647P
Hexobarbitone, 373

Histamine, 209P, 509, 677P, 803
Histamine wheal, 497
Hormonal effects, 634P
5-HT_2 receptor antagonist, 625P
Human cytochrome P-450, 363
Human liver, 23
Human milk, 45, 107
Human plasma, 226P
Human semen, 179
Hydroxychloroquine, 303
5-hydroxytryptamine, 261
3-hydroxyquinidine, 415
Hypertension, 53, 215P, 323, 535, 618P, 619P, 632P, 643P, 715
Hypothesis testing, 234P
Hyperthyroidism, 675P

ICI 169,369, 625P
ICI 118,551, 675P
Ileostomy, 173
Ileum, 206P
Imidazoles, 23
Immunological basis, 491
Indian females, 604
Indocyanine green, 649P
Indomethacin, 119, 167, 235P, 557
Inflammatory response, 209P
Infrared pupillometer, 200P
Infusion, 589
Inhibition, 23
Initial BP, 535
Inotrope, 669P
Interaction, 79, 191, 285, 330, 547, 644P, 657P
Intermittent claudication, 569
Intra-articular, 563
Intraocular pressure, 89, 659P
Ipratropium, 110
Ipratropium bromide, 295
Ischaemic heart disease, 640P
Ischaemic rest pain, 650P
Isoniazid, 103
Isoprenaline, 547
Ivermectin, 225P

Jejunum, 206P
Judgement analysis, 653P

Ketanserin, 61
Ketoprofen, 210P,765
Kidney transplantation, 474

L-657, 743, 627P
Lamotrigine, 242P
Laser Doppler flowmetry, 206P
Lasers, 267
Leucocytes, 237P
Leukotriene D_4, 110, 677P
Leukotriene antagonist, 235P
Levocabastine, 509
Levodopa, 219P, 619P
Lignocaine, 116, 648P
Lipids, 478
Lisinopril, 618P, 781
Lithium, 195
Liver blood flow, 649P
Liver circulation, 273
Liver cirrhosis, 273
Liver microsomes, 13, 227P, 665P, 667P
Local anaesthetics, 116

MCI-154, 669P
MHPG excretion, 202P
Maxolon, 747
Medication, 646P
Medifoxamine, 645P
Menstrual cycle, 604
Mesenteric vasculature, 691
Metabolism, 403
Metabolites, 285, 415
Methohexitone, 589
Methyl xanthine, 429
Metoclopramide, 201P, 220P, 221P, 469, 474, 741, 747
Metoprolol, 230P, 630P, 655P, 675P, 807
Metronidazole, 45
Mianserin, 238P, 577, 665P, 666P
Microcirculation, 267
Microsomal metabolism, 577
Microvascular tone, 206P
Midazolam, 595
Mifentidine, 407
Milk proteins, 107
Minoxidil, 481
Minute volume, 595
Miosis, 697
Miotic drugs, 200P
Monoclonal antibodies, 363
Mood, 709
Morphine, 223P
Mydriasis, 697
Mydriatic drugs, 200P

Nadolol, 92
Nalbuphine, 79
Naproxen, 41
Natriuresis, 214P
Nedocromil, 110
Neonate, 45
Neuropeptide Y, 633P
Nicardipine, 243P
Nicotine *N*-oxidation, 652P
Nifedipine, 633P, 651P
Nitrazepam, 621P
Nitrendipine, 323
Non-invasive, 155
Non-steroidal anti-inflammatory drugs, 455, 488, 759, 765
Noradrenaline, 203P, 547, 633P
Norfloxacin, 787

Ocular penetration, 92
Oral administration, 407
Oral contraceptives, 791
Osteoarthritic patients, 41
Oxazepam, 224P
Oxcarbazepine, 641P
Oxidation, 791
Oxidation phenotype, 230P
Oxipurinol, 423, 429

Oxprenolol Oros, 435
Oxygen desaturation, 595
Oxypentifylline, 569

p-aminohippurate, 621P
pH-dependent release, 173
PAF antagonist, 65
Pain, 463
Paracetamol, 204P
Parkinsonian patients, 664P
Patients' knowledge, 646P
Penile tumescence, 733
Pentoxifylline, 650P
Performance, 121
Perindopril, 211P, 212P
Pharmacodynamics, 211P, 212P, 403, 415, 557, 672P
Pharmacokinetics, 31, 41, 100, 207P, 210P, 211P, 212P, 216P, 219P, 221P, 231P, 239P, 242P, 285, 303, 315, 323, 330, 385, 403, 407, 415, 445, 469, 497, 557, 589, 604, 618P, 619P, 626P, 637P, 643P, 644P, 645P, 657P, 660P, 664P, 669P, 670P, 672P, 674P, 747, 787, 800
Phenacetin-*o*-deethylase, 363
Phenobarbitone, 205P
Phenylephrine, 232P
Phenytoin, 237P, 330, 577, 666P
Pholcodine, 445
Pindolol, 631P
Piretanide, 143
Pituitary hormones, 79
Plasma concentration, 435
Plasma growth hormone, 202P
Plasma protein binding, 31, 721
Platelet activating factor, 65, 209P
Platelet aggregation, 226P
Platelet function, 651P
Plethysmography, 733
Pneumocystis carinii, 487
Poisoning, 195
Polymorphism, 233P, 234P, 601, 630P
Polytherapy recution, 253
Population study, 791
Portal hypertension, 273
Postoperative, 225P
Postoperative pain, 463
Posture, 238P
Prazosin, 267
Pregnancy, 489
Preoperative administration, 747
Probit plots, 233P
Prochlorperazine, 201P, 222P
Prolactin, 220P, 654P
Propafenone, 489, 629P
Propofol, 187
Propranolol, 100, 121, 675P
Protein binding, 107, 455, 635P, 648P
Psoriasis, 119
Psychomotor function, 503
Psychomotor performance, 79
Pupil response, 625P
Pupillary light reflex, 697
Pupillary responses, 200P
4-pyridylglutethimide, 663P

QT interval, 217P
Quality of life, 628P, 653P
Quinalapril, 478
Quinidine, 415

Radioreceptor assay, 79
Ranitidine, 637P, 643P, 671P
Raynaud's phenomenon, 633P
Reactive metabolites, 13
Regression modelling, 355
Renal clearance, 621P
Renal failure, 204P, 315, 385, 781
Renal function, 423, 619P
Renal transplantation, 626P
Respiration, 79
Responders and non-responders, 759
Return tablet count, 641P
Rheumatoid arthritis, 355
Rifampicin, 643P
Rilmenidine, 703
42068RP, 664P

Salbutamol, 208P, 527, 626P, 646P
Salicylate, 334
Sedation, 503
Sibutramine, 607
SK&F 101468, 654P
SK&F 104353–Z2, 235P, 677P
Skin, 119, 206P, 803
Skin blood flow, 659P
Sleep, 201P
Sodium cromoglycate, 207P, 295
Sodium excretion, 203P
Sodium nitroprusside, 691
Soluble aspirin, 463
Sorbinil, 237P, 577
Spirometry, 709
Standard error of the mean, 197
Statistics, 197
Stereoselective, 230P
Stereoselective metabolism, 665P
Stereoselectivity, 771
Sulphadimidine, 563
Sulphation, 31
Sulphonamides, 23
Synovial fluid, 41
Systolic time intervals, 155, 399

Tenoxicam, 455
Terbinafine, 236P
Terbutaline, 285
Terfenadine, 803
Tertatolol, 643P
(±)-thalidomide, 623P
The Smith Kline & French lecture, 339
Theophylline, 73, 191, 285, 373, 613, 657P, 800
Therapeutic monitoring, 721
Thromboxane A_2, 662P
Thyrotoxicosis, 103
Tiapamil, 183
Tolbutamide hydroxylase, 23
Tolbutamide 4-hydroxylase, 227P
Tomoxetine, 231P
Toxicity, 237P, 577

Tremor, 208P, 527
Trial design, 569
Triamterene, 143
Trigeminal neuralgia, 641P
Trimetazidine, 657P
Trimethoprim, 391, 487
Trimethylaminuria, 241P
Trimipramine, 201P
TSH, 205P
Tubocurarine, 617P

UK-61,260, 669P, 670P
UK-66,914, 672P
Ulcerative colitis, 173
Ultrafiltration, 107
Uraemia, 474
Uraemic binding ihibitors, 229P
Urapidil, 216P
Uric acid, 423
Urinary concentrations, 787

Vagal reflex, 110
Variability, 155
Variegate porphyria, 753
Vasodilatation, 245
Vasodilator, 640P, 669P, 691
Vasodilator haemodynamics, 238P
Veins, 245
Venous system, 797
Verapamil, 213P, 273
Visual evoked potential, 636P

Warfarin, 620P, 648P
Wheal, 113

Xamoterol, 213P, 631P
Xanthine, 429
Xanthine oxidase, 429

Yellow cards, 679
Yohimbine, 733

Zopiclone, 621P, 673P